<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Crighton, GL - 2015 | Cochrane Library</title> <meta content="A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Crighton, GL - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010981.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Crighton, GL - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010981.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010981.pub2" name="dc.identifier" scheme="DOI"/> <meta content="A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation" name="citation_title"/> <meta content="Gemma L Crighton" name="citation_author"/> <meta content="Department of Epidemiology and Preventive Medicine, Monash University and Australian Red Cross Blood Service" name="citation_author_institution"/> <meta content="Lise J Estcourt" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="lise.estcourt@nhsbt.nhs.uk" name="citation_author_email"/> <meta content="Erica M Wood" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Marialena Trivella" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Carolyn Doree" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Simon J Stanworth" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust and University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD010981.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010981.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010981.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010981.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cause of Death; Hematologic Diseases [*therapy]; Hemorrhage [*prevention &amp; control, *therapy]; Platelet Transfusion [adverse effects, *methods, statistics &amp; numerical data]; Randomized Controlled Trials as Topic; *Stem Cell Transplantation; Thrombocytopenia [complications, *therapy]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010981.pub2&amp;doi=10.1002/14651858.CD010981.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010981\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010981\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","hr","ru","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010981.pub2",title:"A therapeutic\\u2010only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation",firstPublishedDate:"Sep 30, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010981.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010981.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010981.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010981.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010981.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010981.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010981.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010981.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010981.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010981.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2281 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010981.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/appendices#CD010981-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/table_n/CD010981StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/table_n/CD010981StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0004">Gemma L Crighton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Lise J Estcourt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0006">Erica M Wood</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0007">Marialena Trivella</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0008">Carolyn Doree</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information#CD010981-cr-0009">Simon J Stanworth</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information/en#CD010981-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010981.pub2">https://doi.org/10.1002/14651858.CD010981.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010981-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010981-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010981-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010981-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010981-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010981-abs-0001" lang="en"> <section id="CD010981-sec-0001"> <h3 class="title" id="CD010981-sec-0001">Background</h3> <p>Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding. </p> <p>This is an update of a Cochrane review first published in 2004 and updated in 2012 that addressed four separate questions: therapeutic‐only versus prophylactic platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments. We have now split this review into four smaller reviews looking at these questions individually; this review is the first part of the original review. </p> </section> <section id="CD010981-sec-0002"> <h3 class="title" id="CD010981-sec-0002">Objectives</h3> <p>To determine whether a therapeutic‐only platelet transfusion policy (platelet transfusions given when patient bleeds) is as effective and safe as a prophylactic platelet transfusion policy (platelet transfusions given to prevent bleeding, usually when the platelet count falls below a given trigger level) in patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation. </p> </section> <section id="CD010981-sec-0003"> <h3 class="title" id="CD010981-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (Cochrane Library 2015, Issue 6), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1950) and ongoing trial databases to 23 July 2015. </p> </section> <section id="CD010981-sec-0004"> <h3 class="title" id="CD010981-sec-0004">Selection criteria</h3> <p>RCTs involving transfusions of platelet concentrates prepared either from individual units of whole blood or by apheresis, and given to prevent or treat bleeding in patients with malignant haematological disorders receiving myelosuppressive chemotherapy or undergoing HSCT. </p> </section> <section id="CD010981-sec-0005"> <h3 class="title" id="CD010981-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by The Cochrane Collaboration.</p> </section> <section id="CD010981-sec-0006"> <h3 class="title" id="CD010981-sec-0006">Main results</h3> <p>We identified seven RCTs that compared therapeutic platelet transfusions to prophylactic platelet transfusions in haematology patients undergoing myelosuppressive chemotherapy or HSCT. One trial is still ongoing, leaving six trials eligible with a total of 1195 participants. These trials were conducted between 1978 and 2013 and enrolled participants from fairly comparable patient populations. We were able to critically appraise five of these studies, which contained separate data for each arm, and were unable to perform quantitative analysis on one study that did not report the numbers of participants in each treatment arm. </p> <p>Overall the quality of evidence per outcome was low to moderate according to the GRADE approach. None of the included studies were at low risk of bias in every domain, and all the studies identified had some threats to validity. We deemed only one study to be at low risk of bias in all domains other than blinding. </p> <p>Two RCTs (801 participants) reported at least one bleeding episode within 30 days of the start of the study. We were unable to perform a meta‐analysis due to considerable statistical heterogeneity between studies. The statistical heterogeneity seen may relate to the different methods used in studies for the assessment and grading of bleeding. The underlying patient diagnostic and treatment categories also appeared to have some effect on bleeding risk. Individually these studies showed a similar effect, that a therapeutic‐only platelet transfusion strategy was associated with an increased risk of clinically significant bleeding compared with a prophylactic platelet transfusion policy. Number of days with a clinically significant bleeding event per participant was higher in the therapeutic‐only group than in the prophylactic group (one RCT; 600 participants; mean difference 0.50, 95% confidence interval (CI) 0.10 to 0.90; moderate‐quality evidence). There was insufficient evidence to determine whether there was any difference in the number of participants with severe or life‐threatening bleeding between a therapeutic‐only transfusion policy and a prophylactic platelet transfusion policy (two RCTs; 801 participants; risk ratio (RR) 4.91, 95% CI 0.86 to 28.12; low‐quality evidence). Two RCTs (801 participants) reported time to first bleeding episode. As there was considerable heterogeneity between the studies, we were unable to perform a meta‐analysis. Both studies individually found that time to first bleeding episode was shorter in the therapeutic‐only group compared with the prophylactic platelet transfusion group. </p> <p>There was insufficient evidence to determine any difference in all‐cause mortality within 30 days of the start of the study using a therapeutic‐only platelet transfusion policy compared with a prophylactic platelet transfusion policy (two RCTs; 629 participants). Mortality was a rare event, and therefore larger studies would be needed to establish the effect of these alternative strategies. There was a clear reduction in the number of platelet transfusions per participant in the therapeutic‐only arm (two RCTs, 991 participants; standardised mean reduction of 0.50 platelet transfusions per participant, 95% CI ‐0.63 to ‐0.37; moderate‐quality evidence). None of the studies reported quality of life. There was no evidence of any difference in the frequency of adverse events, such as transfusion reactions, between a therapeutic‐only and prophylactic platelet transfusion policy (two RCTs; 991 participants; RR 1.02, 95% CI 0.62 to 1.68), although the confidence intervals were wide. </p> </section> <section id="CD010981-sec-0007"> <h3 class="title" id="CD010981-sec-0007">Authors' conclusions</h3> <p>We found low‐ to moderate‐grade evidence that a therapeutic‐only platelet transfusion policy is associated with increased risk of bleeding when compared with a prophylactic platelet transfusion policy in haematology patients who are thrombocytopenic due to myelosuppressive chemotherapy or HSCT. There is insufficient evidence to determine any difference in mortality rates and no evidence of any difference in adverse events between a therapeutic‐only platelet transfusion policy and a prophylactic platelet transfusion policy. A therapeutic‐only platelet transfusion policy is associated with a clear reduction in the number of platelet components administered. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010981-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010981-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010981-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010981-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010981-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010981-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010981-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010981-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010981-abs-0002" lang="en"> <h3>Platelet transfusions to treat bleeding compared with platelet transfusions to prevent bleeding in people with blood cancers receiving intensive treatment </h3> <p><b>Review question</b> </p> <p>We evaluated the evidence regarding whether giving platelet transfusions to patients with low platelets who are bleeding (therapeutically) is as effective and safe as giving platelet transfusions regularly to prevent bleeding (prophylactically). Our target population was people with blood cancers who were receiving intensive myelosuppressive (causing decreased blood cell production) chemotherapy treatments or stem cell transplantation. </p> <p><b>Background</b> </p> <p>People with blood cancers may have low platelet counts because of their underlying cancer. Blood cancers may be treated with chemotherapy and stem cell transplantation, which can cause low platelet counts. Platelet transfusions may be given when the platelet count falls below a prespecified platelet count (for example 10 x 10<sup>9</sup>/L) to prevent bleeding, or they may be given to treat bleeding (such as a prolonged nosebleed or multiple bruises). The routine use of platelet transfusions to prevent bleeding in these patients has not previously been supported by high‐quality evidence. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to July 2015. In this update, we identified seven randomised controlled trials that compared only giving platelet transfusions to treat bleeding versus giving platelet transfusions to prevent and treat bleeding. One trial is still recruiting participants and has not been completed. We reviewed six randomised controlled trials with a total of 1195 participants. These trials were conducted between 1978 and 2013. Five of the trials included adults who were receiving chemotherapy or a stem cell transplantation as treatment for blood cancers. One of the trials included children receiving chemotherapy for leukaemia. </p> <p>Four of the six studies reported funding sources; these were charitable foundations or government funds. </p> <p><b>Key results</b> </p> <p>Giving platelet transfusions to prevent and treat bleeding in patients with low platelet counts due to blood cancers or their treatments may result in a reduction in bleeding when compared with giving platelet transfusions only to treat bleeding. </p> <p>There may not be an increased risk of death or adverse events if platelet transfusions are only given to treat bleeding versus giving platelet transfusions to prevent and treat bleeding, but there was not enough evidence to be certain about this. </p> <p>Giving platelet transfusions only when bleeding occurs probably reduces the number of platelets given. </p> <p>None of the six studies reported any quality‐of‐life outcomes.</p> <p><b>Quality of the evidence</b> </p> <p>The evidence for most of the findings was of low or moderate quality, as patients and their doctors knew which study arm the patient had been put in; outcomes reported in the studies were difficult to compare because bleeding was measured and reported differently; and some outcomes were imprecise, because the outcome did not happen very often (such as death). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010981-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010981-sec-0122"></div> <h3 class="title" id="CD010981-sec-0123">Implications for practice</h3> <section id="CD010981-sec-0123"> <p>Due to the high levels of heterogeneity between the two largest identified trials and difficulties combining individual trials in the meta‐analysis, our results should be interpreted with caution. When reviewing the results of the meta‐analysis and the individual studies' results, there is evidence that a therapeutic‐only platelet transfusion policy is associated with increased risk of bleeding when compared with a prophylactic policy. </p> <p>There was insufficient evidence for the outcomes of mortality, overall survival, or complete remission to determine whether there is a difference between these two transfusion strategies. </p> <p>There was no evidence of any difference in adverse events between a therapeutic‐only and a prophylactic platelet transfusion policy. </p> </section> <h3 class="title" id="CD010981-sec-0124">Implications for research</h3> <section id="CD010981-sec-0124"> <p>One of the main constraints in performing the meta‐analysis in this review was the different time periods in which trials reported bleeding. Implications for future research include standardised consensus time periods for reporting outcomes of interest such as bleeding. </p> <p>Further research is needed to identify the subgroups of patients for which it may be safe to adopt a therapeutic‐only platelet transfusion policy, in particular patients receiving autologous HSCT. Whether the conditioning regimens, indication for HSCT, and number of viable CD34 positive cells in the autologous HSCT have any impact on duration of thrombocytopenia and bleeding rates. Another cohort of haematology patients who currently receive regular platelet transfusions include people with myelodysplasia, and an ongoing trial will be able to add further evidence in this area. Other areas of interest are the differences in leukaemia patients receiving different intensities of chemotherapy, that is induction chemotherapy versus consolidation chemotherapy. </p> <p>Double‐blind, placebo‐controlled RCTs are not feasible to compare a therapeutic‐only versus prophylactic platelet transfusion policy because clinicians will be unblinded when they see the participants' platelet counts rise after receiving a prophylactic platelet transfusion and not rise after receiving a placebo. There is also a safety issue for participants. There is a risk that participants may receive placebo rather than a platelet transfusion when they have severe or life‐threatening bleeding. However, blinding assessors of bleeding to the intervention is feasible if they do not see any of the participants' blood results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010981-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010981-sec-0008"></div> <div class="table" id="CD010981-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation<br/><b>Settings:</b> Hospital inpatient or outpatient setting<br/><b>Intervention:</b> a therapeutic‐only platelet transfusion policy<br/><b>Comparison:</b> a prophylactic platelet transfusion policy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion policy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion policy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 1 bleeding episode up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An estimate of the level of effect could not be made due to differences in the way bleeding was assessed in the 2 studies. A higher proportion of participants had WHO Grade 2 or above bleeding in the therapeutic‐only policy arms in both studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days with significant bleeding per participant up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days with significant bleeding per participant in the intervention groups was<br/><b>0.5 higher</b><br/>(0.1 to 0.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>599</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study reported this outcome over a 30 day follow‐up period (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants with severe or life‐threatening bleeding up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.91</b> <br/>(0.86 to 28.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(3 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(2 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first bleeding episode up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An estimate of the level of effect could not be made due to differences in the way bleeding was assessed in the 2 studies. The time to first WHO Grade 2 or above bleeding episode was shorter in the therapeutic‐only policy arms in both studies. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from all causes up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>629<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 of these 2 studies reported any deaths in either study arm (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). There were 5 deaths in the therapeutic arm (301 participants) and 4 deaths in the prophylactic arm (299 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of platelet transfusions per participant in the intervention groups was<br/><b>0.50 lower</b><br/>(0.63 to 0.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the 6 studies reported any quality‐of‐life outcomes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the quality of evidence by 1 for risk of performance bias and detection bias, due to the lack of blinding.<br/><sup>2</sup> We downgraded the quality of evidence by 1 for imprecision due to wide confidence intervals of the pooled estimates and individual trials contributing to this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010981-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010981-sec-0009"></div> <section id="CD010981-sec-0010"> <h3 class="title" id="CD010981-sec-0010">Description of the condition</h3> <p>Haematological malignancies account for between 8% and 9% of all new cancers reported in the UK and US (<a href="./references#CD010981-bbs2-0159" title="Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR). 1999-2012 Cancer incidence and mortality data [United States Cancer Statistic]. www.nccd.cdc.gov/uscs 2012; (accessed 14 February 2013).">CDC 2012</a>; <a href="./references#CD010981-bbs2-0188" title="Office for National Statistics. Cancer incidence and mortality in the United Kingdom - 2008-2010. www.ons.gov.uk/ons/ 2012 (accessed 14 February 2013).">ONS 2012</a>), and their incidence is increasing (11% to 14% increase in new cases of lymphoma and myeloma between 1991 to 2001 and 2008 to 2010) (<a href="./references#CD010981-bbs2-0158" title=" Cancer Research UK . Percentage change in European age-standardised three year average incidence rates, males, UK, 1991-2001 and 2008-2010. http://www.cancerresearchuk.org/cancer-info/cancerstats/ (Accessed 14 February 2013).">Cancer Research UK 2013</a>). The prevalence of haematological malignancies is also increasing due to increased survival rates (<a href="./references#CD010981-bbs2-0160" title="ColemanMP , RachetB , WoodsLM , MitryE , RigaM , CooperN , et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer2004;90(7):1367-73.">Coleman 2004</a>; <a href="./references#CD010981-bbs2-0196" title="RachetB , MaringeC , NurU , QuaresmaM , ShahA , WoodsLM , et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology 10;4:351-69.">Rachet 2009</a>), which are the result of the introduction of myelosuppressive chemotherapy treatments and use of stem cell transplantation (<a href="./references#CD010981-bbs2-0156" title="BurnettAK , HillsRK , MilliganD , KjeldsenL , KellJ , RussellNH , et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology2011;29(4):369-77.">Burnett 2011</a>; <a href="./references#CD010981-bbs2-0172" title="FieldingAK , RichardsSM , ChopraR , LazarusHM , LitzowMR , BuckG , et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood2007;109(3):944-50. [PMID: 17032921]">Fielding 2007</a>; <a href="./references#CD010981-bbs2-0191" title="PatelB , KirklandK , SzydloR , PearceR , ClarkR , CraddockC , et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica2009;94:1399-406.">Patel 2009</a>). Over 50,000 haematopoietic stem cell transplants (HSCTs) are carried out annually worldwide to treat both malignant and non‐malignant haematological disorders (<a href="./references#CD010981-bbs2-0174" title="GratwohlA , BaldomeroH , AljurfM , PasquiniMC , BouzasLF , YoshimiA , et al. Hematopoietic stem cell transplantation: a global perspective. JAMA2010;303(16):1617-24.">Gratwohl 2010</a>). Autologous HSCT is the most common type of HSCT (57% to 59%) (<a href="./references#CD010981-bbs2-0174" title="GratwohlA , BaldomeroH , AljurfM , PasquiniMC , BouzasLF , YoshimiA , et al. Hematopoietic stem cell transplantation: a global perspective. JAMA2010;303(16):1617-24.">Gratwohl 2010</a>; <a href="./references#CD010981-bbs2-0190" title="PasswegJR , BaldomeroH , GratwohlA , BregniM , CesaroS , DregerP , et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant2012;47(7):906-23.">Passweg 2012</a>). However, myelosuppressive chemotherapy and HSCT can lead to prolonged periods of severe thrombocytopenia (<a href="./references#CD010981-bbs2-0162" title="De la SernaJ , MontesinosP , VellengaE , RayonC , ParodyR , LeonA , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood2008;111(7):3395-402.">De la Serna 2008</a>; <a href="./references#CD010981-bbs2-0176" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564-73.">Heddle 2009a</a>; <a href="./references#CD010981-bbs2-0198" title="RyslerC , StoffelN , BuserA , GratwohlA , TsakirisDA , SternM . Effect of beta-blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets2010;21(1):77-83.">Rysler 2010</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure secondary to chemotherapy or HSCT. The ready availability of platelet concentrates in many countries has undoubtedly made a major contribution in allowing the development of intensive treatment regimens for haematological disorders (malignant and non‐malignant) and other malignancies. The first demonstration of the effectiveness of platelet transfusions was performed in 1910 (<a href="./references#CD010981-bbs2-0164" title="DukeWW . The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion. Journal of the American Medical Association1910;55:1185-92.">Duke 1910</a>). However, it was not until the 1970s and 1980s that the use of platelet transfusions became standard treatment for thrombocytopenic patients with bone marrow failure (<a href="./references#CD010981-bbs2-0019" title="BlajchmanMA , SlichterSJ , HeddleNM , MurphyMF . New strategies for the optimal use of platelet transfusions. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2008;2008:198-204. ">Blajchman 2008</a>). Alongside changes in supportive care, the routine use of platelet transfusions in patients with haematological disorders since that time has led to a marked decrease in the number of haemorrhagic deaths associated with thrombocytopenia (<a href="./references#CD010981-bbs2-0202" title="SlichterSJ . Controversies in platelet transfusion therapy. Annual Reviews of Medicine1980;31:509-40.">Slichter 1980</a>). This has resulted in a considerable increase in the demand for platelet concentrates. Currently, platelet concentrates are the second most frequently used blood component. Administration of platelet transfusions to patients with haematological disorders now constitutes a significant proportion (up to 67%) of all platelets issued (<a href="./references#CD010981-bbs2-0024" title="CameronB , RockG , OlbergB , NeurathD . Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion2007;47(2):206-11. ">Cameron 2007</a>; <a href="./references#CD010981-bbs2-0052" title="GreenoE , McCulloughJ , WeisdorfD . Platelet utilisation and the transfusion trigger: A prospective analysis. Transfusion2007;72(2):201-5. ">Greeno 2007</a>; <a href="./references#CD010981-bbs2-0194" title="PendryK , DaviesT . An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?Blood and Transplant Matters2011;34:17-9.">Pendry 2011</a>), and the majority of these (69%) are given to prevent bleeding (<a href="./references#CD010981-bbs2-0166" title="EstcourtLJ , BirchallJ , LoweD , Grant-CaseyJ , RowleyM , MurphyMF . Platelet transfusions in haematology patients: are we using them appropriately?Vox Sanguinis2012;103(4):284-93.">Estcourt 2012b</a>). </p> <p>Patients can become refractory to platelet transfusions. In an analysis of the <a href="./references#CD010981-bbs2-0131" title="EnrightH , DavisK , GernsheimerT , McCulloughJJ , WoodsonR , SlichterSJ . Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion2003;43(11):1545-52. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine1997;337:1861-70. ">TRAP 1997</a> study data, there was a progressive decrease in the post‐transfusion platelet count increments and time interval between transfusions as the number of preceding transfusions increased (<a href="./references#CD010981-bbs2-0203" title="SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105:4106-14.">Slichter 2005</a>). This effect was seen irrespective of whether the patient developed detectable human leukocyte antigen (HLA) antibodies (<a href="./references#CD010981-bbs2-0203" title="SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105:4106-14.">Slichter 2005</a>). </p> <p>Platelet transfusions are also associated with adverse events. Mild to moderate reactions to platelet transfusions include rigors, fever, and urticaria (<a href="./references#CD010981-bbs2-0177" title="HeddleNM , WebertK . Investigation of acute transfusion reactions. In: MurphyMF , PamphilionDH , editors(s). Practical Transfusion Medicine. 4th edition. Blackwell, 2009:63-89.">Heddle 2009b</a>). These reactions are not life‐threatening, but they can be extremely distressing for the patient. Rarer but more serious sequelae include: anaphylaxis; transfusion‐transmitted infections; transfusion‐related acute lung injury; and immunomodulatory effects (<a href="./references#CD010981-bbs2-0152" title="BensonAB , MossM , SillimanCC . Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. British Journal of Haematology2009;147(4):431-43.">Benson 2009</a>; <a href="./references#CD010981-bbs2-0153" title="BlumbergN , SpinelliSL , FrancisCW , TaubmanMB , PhippsRP . The platelet as an immune cell - CD40 ligand and transfusion immune modulation. Immunology Research2009;45:251-60.">Blumberg 2009</a>; <a href="./references#CD010981-bbs2-0155" title="Bolton-Maggs PHB (Ed) and Cohen H on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report. Serious Hazards of Transfusion (SHOT)2012.">Bolton‐Maggs 2012</a>; <a href="./references#CD010981-bbs2-0177" title="HeddleNM , WebertK . Investigation of acute transfusion reactions. In: MurphyMF , PamphilionDH , editors(s). Practical Transfusion Medicine. 4th edition. Blackwell, 2009:63-89.">Heddle 2009b</a>; <a href="./references#CD010981-bbs2-0182" title="Knowles S (Ed), CohenH , on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report. Serious Hazards of Transfusion (SHOT); 2010.">Knowles 2010</a>; <a href="./references#CD010981-bbs2-0183" title="Knowles S (Ed), CohenH , on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report. Serious Hazards of Transfusion (SHOT); 2011.">Knowles 2011</a>; <a href="./references#CD010981-bbs2-0193" title="PearceS , RoweGP , FieldSP . Screening of platelet for bacterial contamination at the Welsh Blood Service. Transfusion Medicine2011;21(1):25-32.">Pearce 2011</a>; <a href="./references#CD010981-bbs2-0195" title="PopovskyMA , MooreSB . Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion1985;25:573-7.">Popovsky 1985</a>; <a href="./references#CD010981-bbs2-0201" title="SillimanCC , BoshkovLK , MehdizadehkashiZ , ElziDJ , DickeyWO , PodloskyL , et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood2003;101(2):454-62.">Silliman 2003</a>). </p> <p>Any strategy that can safely decrease the need for prophylactic platelet transfusions in haematology patients will have significant logistical and financial implications as well as decreasing patients’ exposure to the risks of transfusion. </p> </section> <section id="CD010981-sec-0011"> <h3 class="title" id="CD010981-sec-0011">Description of the intervention</h3> <p>Platelet transfusions have an obvious beneficial effect in the management of active bleeding in patients with haematological malignancy and severe thrombocytopenia. However, questions still remain about how this limited resource should be used to prevent severe and life‐threatening bleeding (<a href="./references#CD010981-bbs2-0165" title="EstcourtLJ , StanworthSJ , MurphyMF . Platelet transfusions for patients with haematological malignancies: who needs them?British Journal of Haematology2011;154(4):425-40.">Estcourt 2011</a>). Prophylactic platelet transfusions for patients with chemotherapy‐induced thrombocytopenia became standard practice following the publication of several small randomised controlled trials (RCTs) in the late 1970s and early 1980s (<a href="./references#CD010981-bbs2-0064" title="HigbyDJ , CohenE , HollandJF , SinksL . The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion1974;14:440-5. ">Higby 1974</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). </p> <p>This review did not focus on the absolute need for platelet transfusions in this patient population, but instead on whether a prophylactic platelet transfusion policy is required. The standard practice in most haematology units in high‐income countries is to use prophylactic transfusions, in line with guidelines (<a href="./references#CD010981-bbs2-0150" title="British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology2003;122:10-23.">BCSH 2003</a>; <a href="./references#CD010981-bbs2-0151" title="British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology2004;124(4):433-53.">BCSH 2004</a>; <a href="./references#CD010981-bbs2-0154" title="The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board. Platelet concentrates. Cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfusion Medicine and Hemotherapy2009;36:372-82.">Board 2009</a>; <a href="./references#CD010981-bbs2-0187" title="National Blood Authority. The National Blood Authority’s Patient Blood Management Guideline: Module 3 – Medical. National Blood Authority, 2012.">NBA 2012</a>; <a href="./references#CD010981-bbs2-0199" title="SchifferCA , AndersonKC , BennettCL , BernsteinS , EltingLS , GoldsmithM , et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology2001;19:1519-38.">Schiffer 2001</a>; <a href="./references#CD010981-bbs2-0119" title="SlichterSJ . Evidence-based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology2007;2007:172-8. ">Slichter 2007</a>; <a href="./references#CD010981-bbs2-0209" title="TinmouthAT . Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. In: Canadian Blood Services. 4th edition. Canadian Blood Services, 2007.">Tinmouth 2007</a>). The experimental intervention will be to give platelet transfusions only when bleeding occurs (therapeutic‐only strategy). </p> </section> <section id="CD010981-sec-0012"> <h3 class="title" id="CD010981-sec-0012">How the intervention might work</h3> <section id="CD010981-sec-0013"> <h4 class="title">Prophylactic versus therapeutic‐only platelet transfusions</h4> <p>A retrospective review of almost 3000 thrombocytopenic adult patients over a 10‐year period showed no relationship between the first morning platelet count, or the lowest platelet count of the day, and the risk of severe or life‐threatening bleeding (World Health Organization (WHO) Grade 3 to 4 bleeding) (<a href="./references#CD010981-bbs2-0042" title="FriedmannAM , SengulH , LehmannH , SchwartzC , GoodmanS . Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients?Transfusion Medicine Reviews2002;16:34-45. ">Friedmann 2002</a>). This raised the question as to whether a threshold‐defined prophylactic platelet transfusion approach is appropriate. Further large studies have confirmed this finding and also shown no relationship between the morning platelet count and the risk of clinically significant bleeding (WHO Grade 2 bleeding) the following day except at very low platelet counts (≤ 5 x 10<sup>9</sup>/L) (<a href="./references#CD010981-bbs2-0120" title="JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A-20A. JosephsonCD , GrangerS , AssmannSF , CastillejoMI , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia [         ]. Blood2012;120(4):748-60. NCT00128713. Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713. Accessed 16 April 2010. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600-13. SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78-84. ">Slichter 2010</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Further support for the absence of a relationship between the severity of thrombocytopenia and bleeding came from a review of case reports of severe intracranial haemorrhage, which found no clear evidence for an association between the occurrence of major intracranial bleeding and absolute platelet count just prior to the onset of severe bleeding (<a href="./references#CD010981-bbs2-0204" title="StanworthSJ , HydeC , BrunskillS , MurphyMF . Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?British Journal of Haematology2005;131:588-95.">Stanworth 2005</a>). Thus, the overall benefit of a prophylactic platelet transfusion policy over a policy to give platelets therapeutically only, using a platelet count threshold, has not been established. A recent trial suggested that a therapeutic‐only platelet transfusion policy might become the new standard of care in selected patients, however the primary endpoint for this study was a reduction in the number of platelet transfusions, rather than a clinical outcome such as bleeding (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). The Trial of Platelet Prophylaxis (TOPPS) is another large RCT that has been recently completed and may provide additional evidence (<a href="./references#CD010981-bbs2-0205" title="StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71.">Stanworth 2010</a>; <a href="./references#CD010981-bbs2-0206" title="StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120(Supplement 1):Abstract 1.">Stanworth 2012</a>). </p> </section> <section id="CD010981-sec-0014"> <h4 class="title">Assessment of bleeding</h4> <p>A bleeding assessment is a more clinically relevant measure of the effect of platelet transfusions than surrogate markers such as platelet count increment. </p> <p>Any review that uses bleeding as a primary outcome measure needs to assess the way that the trials have recorded bleeding. Unfortunately, bleeding assessment and recording have varied markedly between trials (<a href="./references#CD010981-bbs2-0161" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion2004;44:1135-42.">Cook 2004</a>; <a href="./references#CD010981-bbs2-0167" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials. Transfusion2013;53(7):1531-43.">Estcourt 2013</a>; <a href="./references#CD010981-bbs2-0062" title="HeddleNM , CookRJ , WebertKE , SigouinC , RebullaP . Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion2003;43:742-52. ">Heddle 2003</a>). </p> <p>Retrospective analysis of bleeding leads to a risk of bias because bleeding events may be missed, and only more severe bleeding is likely to have been documented. Prospective bleeding assessment forms provide more information and are less likely to miss bleeding events. However, different assessors may grade the same bleed differently, and it is very difficult to blind the assessor to the intervention. </p> <p>The majority of trials have used the WHO system, or a modification of it, for grading bleeding (<a href="./references#CD010981-bbs2-0167" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials. Transfusion2013;53(7):1531-43.">Estcourt 2013</a>; <a href="./references#CD010981-bbs2-0184" title="KorethR , WeinertC , WeisdorfDJ , KeyNS . Measurement of bleeding severity: a critical review. Transfusion2004;44:605-17.">Koreth 2004</a>; <a href="./references#CD010981-bbs2-0211" title="World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48 edition. Geneva: World Health Organization, 1979.">WHO 1979</a>). One limitation of all the scoring systems that are based on the WHO system is that the categories are relatively broad and subjective. This means that a small change in a patient's bleeding risk may not be detected. Another limitation is that the modified WHO categories are partially defined by whether a bleeding patient requires a blood transfusion. The threshold for intervention may vary between clinicians and institutions, and so the same level of bleeding could be graded differently in different institutions. </p> <p>The definition of what constitutes clinically significant bleeding has varied between studies. Although the majority of more recent platelet transfusion studies now classify it as WHO Grade 2 or above (<a href="./references#CD010981-bbs2-0176" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564-73.">Heddle 2009a</a>; <a href="./references#CD010981-bbs2-0120" title="JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A-20A. JosephsonCD , GrangerS , AssmannSF , CastillejoMI , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia [         ]. Blood2012;120(4):748-60. NCT00128713. Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713. Accessed 16 April 2010. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600-13. SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78-84. ">Slichter 2010</a>; <a href="./references#CD010981-bbs2-0206" title="StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120(Supplement 1):Abstract 1.">Stanworth 2012</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), there has been greater heterogeneity in the past (<a href="./references#CD010981-bbs2-0161" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion2004;44:1135-42.">Cook 2004</a>; <a href="./references#CD010981-bbs2-0167" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials. Transfusion2013;53(7):1531-43.">Estcourt 2013</a>; <a href="./references#CD010981-bbs2-0184" title="KorethR , WeinertC , WeisdorfDJ , KeyNS . Measurement of bleeding severity: a critical review. Transfusion2004;44:605-17.">Koreth 2004</a>). The difficulties of assessing and grading bleeding may limit the ability to compare results between studies, and this needs to be kept in mind when reviewing the evidence for the effectiveness of prophylactic platelet transfusions. </p> </section> </section> <section id="CD010981-sec-0015"> <h3 class="title" id="CD010981-sec-0015">Why it is important to do this review</h3> <p>Considerable advances have been made in platelet transfusion therapy in the last 40 years. However, three major areas continue to provoke debate: </p> <p> <ul id="CD010981-list-0001"> <li> <p>Firstly, what is the optimal prophylactic platelet dose to prevent thrombocytopenic bleeding? </p> </li> <li> <p>Secondly, which threshold should be used to trigger the transfusion of prophylactic platelets? </p> </li> <li> <p>Thirdly, is a therapeutic‐only platelet transfusion strategy as effective and safe as a prophylactic platelet transfusion policy for the prevention or control (or both) of life‐threatening bleeding in this setting? </p> </li> </ul> </p> <p>The initial formulation of this Cochrane review attempted to answer these questions, but there was insufficient evidence available at the time for us to draw any definitive conclusions (<a href="./references#CD010981-bbs2-0214" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub2]">Stanworth 2004</a>). Although the original review was recently updated (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>), it is now outdated because two new large studies have recently been completed (<a href="./references#CD010981-bbs2-0206" title="StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120(Supplement 1):Abstract 1.">Stanworth 2012</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Sufficient additional information regarding these different questions now exists. For clarity and simplicity, we have split the review to answer each question separately. </p> <p>This review will focus solely on the third question: Is a therapeutic‐only platelet transfusion strategy as effective and safe as a prophylactic platelet transfusion policy for the prevention or control (or both) of life‐threatening bleeding in the setting of thrombocytopenia? </p> <p>We will assess the other two questions in two separate reviews, with an additional third review assessing the use of alternative agents instead of prophylactic platelet transfusions. </p> <p>Avoiding the need for unnecessary prophylactic platelet transfusions in patients with haematologic malignancies will have significant logistical and financial implications for national health services as well as decreasing patients' exposure to the risks of transfusion. This knowledge is perhaps even more important in the development of platelet transfusion strategies in low‐income countries, where access to blood components is much more limited (<a href="./references#CD010981-bbs2-0210" title="VermaA , AgarwalP . Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfusion and Apheresis Science2009;41(2):145-9.">Verma 2009</a>). </p> <p>This review will not assess whether there are any differences in the efficacy of apheresis versus whole‐blood‐derived platelet products, the efficacy of pathogen‐reduced platelet components, the efficacy of HLA‐matched versus random‐donor platelets, or differences between ABO‐identical and ABO‐non‐identical platelet transfusions. Recent systematic reviews have covered these topics (<a href="./references#CD010981-bbs2-0157" title="ButlerC , DoreeC , EstcourtLJ , TrivellaM , HopewellS , Brunskill, SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD009072. [DOI: 10.1002/14651858.CD009072]">Butler 2013</a>; <a href="./references#CD010981-bbs2-0175" title="HeddleNM , ArnoldDM , BoyeD , WebertKE , ReszI , DumontLJ . Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion2008;48(7):1447-58.">Heddle 2008</a>; <a href="./references#CD010981-bbs2-0192" title="PavenskiK , RebullaP , DuquesnoyR , SawCL , SlichterSJ , TanaelS , et al, International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies (ICTMG) Collaborators. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013 [Epub ahead of print]. [DOI: 10.1111/trf.12175]">Pavenski 2013</a>; <a href="./references#CD010981-bbs2-0113" title="ShehataN , TinmouthA , NaglieG , FreedmanJ , WilsonK . ABO-identical versus non-identical platelet transfusion: a systematic review. Transfusion2009;49:2442-53. ">Shehata 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010981-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010981-sec-0016"></div> <p>To determine whether a therapeutic‐only platelet transfusion policy (platelet transfusions given when patient bleeds) is as effective and safe as a prophylactic platelet transfusion policy (platelet transfusions given to prevent bleeding, usually when the platelet count falls below a given trigger level) in patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation (<a href="./references#CD010981-bbs2-0213" title="EstcourtLJ , CrightonGL , WoodEM , StanworthS , TrivellaM , DoreeC , et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010981. [DOI: 10.1002/14651858.CD010981]">Estcourt 2014d</a>). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010981-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010981-sec-0017"></div> <section id="CD010981-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010981-sec-0019"> <h4 class="title">Types of studies</h4> <p>We only included randomised controlled trials (RCTs) in this review, irrespective of language or publication status. </p> </section> <section id="CD010981-sec-0020"> <h4 class="title">Types of participants</h4> <p>People with haematological disorders receiving treatment with myelosuppressive chemotherapy or HSCT (or both). We included people of all ages, in both inpatient and outpatient clinical settings. </p> <p>If trials consisted of mixed populations of patients, for example patients with diagnoses of solid tumours, we used only data from the haematological subgroups. If subgroup data for haematological patients was not provided (after contacting the authors of the trial), the trial was excluded if fewer than 80% of participants had a haematological disorder. We excluded any patients who were not being treated with myelosuppressive chemotherapy or a HSCT. We included patients with non‐malignant haematological disorders (for example aplastic anaemia, congenital bone marrow failure syndromes) if they were being treated with an allogeneic stem cell transplant. These patients would be expected to be thrombocytopenic during pre‐transplant conditioning therapy and during transplantation period, requiring platelet transfusion support. </p> </section> <section id="CD010981-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Participants in both treatment arms received transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis to treat bleeding (therapeutic platelet transfusions). Participants in the control arm also received prophylactic platelet transfusions. Prophylactic platelet transfusions are typically given when the platelet count falls below a given threshold. There was no restriction on the dose, frequency, type of platelet component, or transfusion trigger of the platelet transfusions, but where it was available we took this information into account in the analysis. </p> <p>We included the following comparisons:</p> <p> <ul id="CD010981-list-0002"> <li> <p>Therapeutic‐only platelet transfusions (on‐demand triggered by bleeding) versus prophylactic platelet transfusions </p> </li> <li> <p>Placebo versus prophylactic platelet transfusions</p> </li> </ul> </p> </section> <section id="CD010981-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD010981-sec-0023"> <h5 class="title">Primary outcomes</h5> <p>Number and severity of bleeding episodes within 30 days from the start of the study:</p> <p> <ol id="CD010981-list-0003"> <li> <p>The number of participants with at least one bleeding episode.</p> </li> <li> <p>The total number of days on which bleeding occurred per participant.</p> </li> <li> <p>The number of participants with at least one episode of severe or life‐threatening bleeding. </p> </li> <li> <p>Time to first bleeding episode from the start of the study.</p> </li> </ol> </p> </section> <section id="CD010981-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010981-list-0004"> <li> <p>Mortality (all causes, secondary to bleeding, and secondary to infection) within 30 and 90 days from the start of the study. </p> </li> <li> <p>Number of platelet transfusions per participant and number of platelet components per participant within 30 days from the start of the study. </p> </li> <li> <p>Number of red cell transfusions per participant and number of red cell components per participant within 30 days from the start of the study. </p> </li> <li> <p>Platelet transfusion interval within 30 days from the start of the study.</p> </li> <li> <p>Proportion of participants requiring additional interventions to stop bleeding (surgical; medical, e.g. tranexamic acid; other blood products, e.g. fresh frozen plasma, cryoprecipitate) within 30 days from the start of the study. </p> </li> <li> <p>Overall survival within 30, 90, and 180 days from the start of the study.</p> </li> <li> <p>Proportion of participants achieving complete remission within 30 and 90 days from the start of the study. </p> </li> <li> <p>The total time in hospital within 30 days from the start of the study.</p> </li> <li> <p>Adverse effects of treatments (transfusion reactions, thromboembolism, transfusion‐transmitted infection, development of platelet antibodies, development of platelet refractoriness) within 30 and 90 days from the start of the study. </p> </li> <li> <p>Quality of life, as defined by the individual studies.</p> </li> </ol> </p> <p>We expressed all primary and secondary outcomes in the formats defined in the <a href="#CD010981-sec-0042">Measures of treatment effect</a> section of this protocol if data were available. We planned to report the following two of our outcomes as a narrative: </p> <p> <ul id="CD010981-list-0005"> <li> <p>Assessment of quality of life, as there is no definitive patient‐reported outcome measure for this patient group (<a href="./references#CD010981-bbs2-0171" title="EstcourtLJ , PinchonD , SymingtonE , KellyAM , DoreeC , BrunskillS , et al. Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion2014;54(4):1166-79. [DOI: 10.1111/trf.12441]">Estcourt 2014e</a>). </p> </li> <li> <p>Platelet transfusion interval, which can be calculated in many different ways, and we expected that the exact methodology would not be reported sufficiently to allow us to combine the data. </p> </li> </ul> </p> <p>However, none of the included studies reported either of these outcomes.</p> </section> </section> </section> <section id="CD010981-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The Systematic Review Initiative Information Specialist (CD) formulated new search strategies in collaboration with the Cochrane Haematological Malignancies Review Group based on those used in previous versions of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>; <a href="./references#CD010981-bbs2-0214" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub2]">Stanworth 2004</a>). </p> <section id="CD010981-sec-0026"> <h4 class="title">Electronic searches</h4> <section id="CD010981-sec-0027"> <h5 class="title">Bibliographic databases</h5> <p>We searched for RCTs in the following databases:</p> <p> <ul id="CD010981-list-0006"> <li> <p>CENTRAL (Cochrane Library 2015, Issue 6, 23 July 2015) (<a href="./appendices#CD010981-sec-0128">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (OvidSP, 1946 to 23 July 2015) (<a href="./appendices#CD010981-sec-0129">Appendix 2</a>) </p> </li> <li> <p>PubMed (epublications only, on 23 July 2015) (<a href="./appendices#CD010981-sec-0130">Appendix 3</a>) </p> </li> <li> <p>Embase (OvidSP, 1974 to 23 July 2015) (<a href="./appendices#CD010981-sec-0131">Appendix 4</a>) </p> </li> <li> <p>CINAHL (EBSCOhost, 1937 to 23 July 2015) (<a href="./appendices#CD010981-sec-0132">Appendix 5</a>) </p> </li> <li> <p>Transfusion Evidence Library (<a href="http://www.transfusionevidencelibrary.com" target="_blank">www.transfusionevidencelibrary.com</a>) (1950 to 23 July 2015) (<a href="./appendices#CD010981-sec-0133">Appendix 6</a>) </p> </li> <li> <p>Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (Thomson Reuters, 1990 to 23 July 2015) (<a href="./appendices#CD010981-sec-0134">Appendix 7</a>) </p> </li> <li> <p>LILACS (BIREME/PAHO/WHO, 1982 to 23 July 2015) (<a href="./appendices#CD010981-sec-0135">Appendix 8</a>) </p> </li> <li> <p>IndMed (ICMR‐NIC, 1986 to 23 July 2015) (<a href="./appendices#CD010981-sec-0136">Appendix 9</a>) </p> </li> <li> <p>KoreaMed (KAMJE, 1997 to 23 July 2015) (<a href="./appendices#CD010981-sec-0137">Appendix 10</a>) </p> </li> <li> <p>PakMediNet (2001 to 23 July 2015) (<a href="./appendices#CD010981-sec-0137">Appendix 10</a>) </p> </li> </ul> </p> <p>We updated searches from the original search (version 1) in January 2002, <a href="./references#CD010981-bbs2-0214" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub2]">Stanworth 2004</a>, and the updated search (version 2) in November 2011, <a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>. We did not re‐screen the original search strategies and instead placed date restrictions from the date of the final search in the preceding review (10 November 2011) to 23 July 2015 for four databases included in version 2 of the review (CENTRAL, MEDLINE, Embase and CINAHL). The other databases had no date restrictions. </p> <p>We combined searches in MEDLINE, Embase, and CINAHL with adaptations of the Cochrane RCT search filters, as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010981-bbs2-0186" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Lefebvre 2011</a>). </p> </section> <section id="CD010981-sec-0028"> <h5 class="title">Databases of ongoing trials</h5> <p>We also searched ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/search" target="_blank">http://clinicaltrials.gov/ct2/search</a>) (<a href="./appendices#CD010981-sec-0138">Appendix 11</a>), the WHO International Clinical Trials Registry (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) (<a href="./appendices#CD010981-sec-0138">Appendix 11</a>), the ISRCTN Register (<a href="http://www.controlled-trials.com/isrctn/" target="_blank">http://www.controlled-trials.com/isrctn/</a>) (<a href="./appendices#CD010981-sec-0139">Appendix 12</a>), the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/ctr-search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search</a>) (<a href="./appendices#CD010981-sec-0139">Appendix 12</a>), and the Hong Kong Clinical Trials Register (<a href="http://www.hkclinicaltrials.com/" target="_blank">http://www.hkclinicaltrials.com/</a>) (<a href="./appendices#CD010981-sec-0140">Appendix 13</a>) in order to identify ongoing trials. </p> <p>We have presented all new search strategies as indicated in Appendices 1 to 13. We have presented search strategies for both the version 1 (2002) and version 2 (2011) searches in <a href="./appendices#CD010981-sec-0141">Appendix 14</a>. </p> </section> </section> <section id="CD010981-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We augmented database searching with the following:</p> <section id="CD010981-sec-0030"> <h5 class="title">Handsearching of reference lists</h5> <p>We checked references of all included trials, relevant review articles, and current treatment guidelines for further literature. We limited these searches to the 'first generation' reference lists. </p> </section> <section id="CD010981-sec-0031"> <h5 class="title">Personal contacts</h5> <p>We contacted authors of relevant studies, study groups, and experts worldwide known to be active in the field for unpublished material or further information on ongoing studies. </p> </section> </section> </section> <section id="CD010981-sec-0032"> <h3 class="title" id="CD010981-sec-0032">Data collection and analysis</h3> <section id="CD010981-sec-0033"> <h4 class="title">Selection of studies</h4> <p>We updated the selection of studies from the selection of studies performed for the update (version 2) of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>). </p> <p>Two out of three independent review authors (GC and LE) or (LE and CD) initially screened all electronically derived citations and abstracts of papers identified by the review search strategy for relevance. We excluded studies clearly irrelevant at this stage. Two review authors (GC, LE) independently formally assessed the full texts of all potentially relevant trials for eligibility against the criteria outlined above. We resolved all disagreements by discussion without needing to consult a third review author (SS). We sought further information from study authors if the article contained insufficient data to make a decision about eligibility. We designed a study eligibility form for trials of platelet transfusion to help in the assessment of relevance, which included ascertaining whether the participants had haematological disorders, and whether two groups could be defined in the trial on the basis of a therapeutic‐only versus prophylactic platelet transfusion strategy. We recorded the reasons for excluding potentially relevant studies. </p> </section> <section id="CD010981-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We updated the data extraction from the data extraction performed for the previous version of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>). This included data extraction for all new studies included since the previous review and also for all review outcomes that were not part of the previous review (for example platelet transfusion interval, quality of life). </p> <p>Two review authors (GC, LE) conducted the data extraction according to the guidelines proposed by The Cochrane Collaboration (<a href="./references#CD010981-bbs2-0178" title="HigginsJPT , Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). Potential disagreements between the review authors were resolved by consensus. The review authors were not blinded to names of authors, institutions, journals, or the outcomes of the trials. The data extraction forms were piloted in the previous version of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>). Due to minor changes in the format, the forms were piloted on a further study; thereafter, the two review authors (GC, LE) independently extracted data for all the studies. The following data were extracted. </p> <section id="CD010981-sec-0035"> <h5 class="title">General information</h5> <p>Review author's name, date of data extraction, study ID, first author of study, author's contact address (if available), citation of paper, objectives of the trial.  </p> </section> <section id="CD010981-sec-0036"> <h5 class="title">Trial details</h5> <p>Trial design, location, setting, sample size, power calculation, treatment allocation, randomisation, blinding, inclusion and exclusion criteria, reasons for exclusion, comparability of groups, length of follow‐up, stratification, stopping rules described, statistical analysis, results, conclusion, and funding. </p> </section> <section id="CD010981-sec-0037"> <h5 class="title">Characteristics of participants</h5> <p>Age, gender, ethnicity, total number recruited, total number randomised, total number analysed, types of haematological disease, lost to follow‐up numbers, dropouts (percentage in each arm) with reasons, protocol violations, previous treatments, current treatment, prognostic factors. </p> </section> <section id="CD010981-sec-0038"> <h5 class="title">Interventions</h5> <p>Experimental and control interventions, type of platelet given, timing of intervention, dosage of platelet given, compliance to interventions, additional interventions given especially in relation to red cell transfusions, any differences between interventions. </p> </section> <section id="CD010981-sec-0039"> <h5 class="title">Assessment of bias</h5> <p>Sequence generation, allocation concealment, blinding (participants, personnel, and outcome assessors), incomplete outcome data, selective outcome reporting, other sources of bias. </p> </section> <section id="CD010981-sec-0040"> <h5 class="title">Outcomes measured</h5> <p> <ul id="CD010981-list-0007"> <li> <p>Number and severity of bleeding episodes.</p> </li> <li> <p>Time to first bleeding episode.</p> </li> <li> <p>Mortality (all causes), and mortality due to bleeding.</p> </li> <li> <p>Overall survival.</p> </li> <li> <p>Proportion of participants achieving complete remission.</p> </li> <li> <p>Time in hospital.</p> </li> <li> <p>Number of platelet transfusions and platelet components.</p> </li> <li> <p>Number of red cell transfusions and red cell components.</p> </li> <li> <p>Platelet transfusion interval.</p> </li> <li> <p>Proportion of participants requiring additional interventions to stop bleeding (surgical; medical, e.g. tranexamic acid; other blood products, e.g. fresh frozen plasma, cryoprecipitate). </p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Adverse effects of treatments (e.g. transfusion reactions, thromboembolism, transfusion‐transmitted infection, development of platelet antibodies, or platelet refractoriness). </p> </li> </ul> </p> <p>We used both full‐text versions and abstracts to retrieve the data. We extracted publications reporting on more than one trial using one data extraction form for each trial. We extracted trials reported in more than one publication on one form only. Where these sources provided insufficient information, we contacted authors and study groups for additional details. </p> <p>One review author performed data entry into software, and a second review author checked it for accuracy. </p> </section> </section> <section id="CD010981-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We updated the 'Risk of bias' assessment from the 'Risk of bias' assessment performed for the previous version of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>). </p> <p>Two review authors (GC, LE) assessed all newly included studies for possible risk of bias (as described in the <i>Cochrane Handbook</i> <i>for Systematic Reviews of Interventions</i> (<a href="./references#CD010981-bbs2-0180" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011c</a>)). The assessment included information about the design, conduct, and analysis of the trial. We evaluated each criterion on a three‐point scale: low risk of bias, high risk of bias, or unclear. To assess risk of bias, we included the following questions in the 'Risk of bias' table for each included study: </p> <p> <ul id="CD010981-list-0008"> <li> <p>Was the allocation sequence adequately generated?</p> </li> <li> <p>Was allocation adequately concealed?</p> </li> <li> <p>Was knowledge of the allocated intervention adequately prevented during the study (including an assessment of blinding of participants, personnel, and outcome assessors)? </p> </li> <li> <p>Were incomplete outcome data adequately addressed (for each outcome separately)?</p> </li> <li> <p>Are reports of the study free of selective outcome reporting?</p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> <li> <p>Was the protocol deviation balanced between treatment arms?</p> </li> </ul> </p> </section> <section id="CD010981-sec-0042"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we recorded the number of outcomes in treatment and control groups and estimated the treatment effect measures across individual studies as the relative effect measures (risk ratio (RR) with 95% confidence intervals (CIs)). </p> <p>For continuous outcomes, we recorded the mean and standard deviations. For continuous outcomes measured using the same scale, the effect measure was the mean difference with 95% CIs, or the standardised mean difference for outcomes measured using different scales. </p> <p>For time‐to‐event outcomes we extracted the hazard ratio from published data according to <a href="./references#CD010981-bbs2-0189" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a> and <a href="./references#CD010981-bbs2-0208" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16). [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>. </p> <p>If appropriate, we reported the number needed to treat to benefit with CIs and the number needed to treat to harm with CIs. </p> <p>If we could not report the data available in any of the formats described above, we performed a narrative report. </p> </section> <section id="CD010981-sec-0043"> <h4 class="title">Unit of analysis issues</h4> <p>We did not prespecify in the protocol how we would deal with any unit of analysis issues. In one study (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), there were unit of analysis issues for the study's secondary outcomes. Some outcomes were reported per treatment cycle rather than per participant, and some participants received more than one cycle of chemotherapy. We resolved this by only using data within meta‐analyses for participants who had received only one cycle of treatment (autologous stem cell transplant patients). We have requested data from the author so that we can include data on all participants within a subsequent review. The study's primary outcome adjusted for repeated courses of chemotherapy (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>We did not prespecify in the protocol how we would deal with multi‐arm studies. One study, <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, was a factorial RCT and included four arms: 1) therapeutic (T)/blood bank (BB)/random‐donor platelets, 2) T/single donor (SD), 3) prophylactic (P)/BB and 4) P/SD. For our study outcomes of interest, aggregate data comparing the therapeutic and prophylactic were provided by the author. </p> </section> <section id="CD010981-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010981-bbs2-0179" title="HigginsJPT , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011b</a>). We contacted four authors to obtain information that was missing or unclear in the published report, of which two authors supplied missing data (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). One author searched for missing data but it was no longer available (<a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>). One author has agreed to provide additional data; this data is not yet available and will be incorporated into the next version of this review (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>In trials that included participants with haematological disorders as well as participants with solid tumours or non‐malignant haematological disorders, we extracted data for the haematology subgroup that was receiving myelosuppressive chemotherapy or stem cell transplantation from the general trial data. </p> <p>When data were missing within an outcome, the preferred analysis was intention‐to‐treat analysis. We recorded the number of participants lost to follow‐up for each trial. </p> </section> <section id="CD010981-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>If we considered studies to be sufficiently homogenous in their study design, we conducted a meta‐analysis and assessed the statistical heterogeneity (<a href="./references#CD010981-bbs2-0163" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). We assessed statistical heterogeneity of treatment effects between trials using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1. We used the I<sup>2</sup> statistic to quantify possible heterogeneity (I<sup>2</sup> greater than 50%, moderate heterogeneity; I<sup>2</sup> greater than 80%, considerable heterogeneity). We explored potential causes of heterogeneity by sensitivity and subgroup analyses if possible. </p> </section> <section id="CD010981-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not perform a formal assessment of potential publication bias (small‐trial bias) by generating a funnel plot and statistically test using a linear regression test (<a href="./references#CD010981-bbs2-0207" title="SterneJAC , EggerM , Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Sterne 2011</a>), because the review included fewer than 10 trials. </p> </section> <section id="CD010981-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We performed analyses according to the recommendations of The Cochrane Collaboration (<a href="./references#CD010981-bbs2-0163" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). We used aggregated data for analysis. For statistical analysis, we entered data into <a href="./references#CD010981-bbs2-0197" title="The Cochrane CollaborationReview Manager 5 (RevMan). The Nordic Cochrane Centre, Version 5.3. Copenhagen: The Cochrane Collaboration, 2012.">Review Manager 5.3</a>. </p> <p>Where meta‐analysis was feasible, we used the fixed‐effect model for pooling the data. We used the Mantel‐Haenszel method for dichotomous outcomes, and the inverse‐variance method for continuous outcomes. We employed the generic inverse‐variance method for time‐to‐event outcomes. </p> <p>We used the random‐effects model for sensitivity analyses as part of the exploration of heterogeneity. If we found heterogeneity, as expressed by the I<sup>2</sup>, to be above 50%, we reported both the fixed‐effect and random‐effects models. If we found heterogeneity to be above 80%, we did not perform a meta‐analysis and commented on results as a narrative. </p> <p>We used GRADEprofiler <a href="./references#CD010981-bbs2-0173" title="McMaster UniversityGRADEpro [www.gradepro.org]. McMaster University. McMaster University, 2015.">GRADE 2014</a> to create 'Summary of findings' tables as suggested in the <i>Cochrane Handbook</i> <i>for Systematic Reviews of Interventions</i> (<a href="./references#CD010981-bbs2-0200" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schünemann 2011</a>). This included the number and severity of bleeding episodes within 30 days from the start of the study (number of participants with at least one bleeding episode; number of days on which bleeding occurred; number of participants with severe or life‐threatening bleeding; time to first bleeding episode), number of platelet transfusions within 30 days from the start of the study, overall mortality at 30 days, and quality of life. </p> </section> <section id="CD010981-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Two subgroup analyses were prespecified in the previous version of this review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>): fever and participants' diagnostic and treatment subgroups. We considered performing subgroup analysis on the following prespecified characteristics, if appropriate: </p> <p> <ul id="CD010981-list-0009"> <li> <p>Presence of fever (&gt; 38ºC).</p> </li> <li> <p>Underlying disease.</p> </li> <li> <p>Type of treatment (autologous HSCT, allogeneic HSCT, or chemotherapy alone).</p> </li> <li> <p>Age of the participant (paediatric, adults, older adults (&gt; 60 years)).</p> </li> </ul> </p> <p>Due to lack of data, we performed only three of these subgroup analyses; underlying disease, type of treatment, and age of participant. </p> <p>We did not perform meta‐regression because no subgroup contained more than 10 studies (<a href="./references#CD010981-bbs2-0163" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). We commented on differences between subgroups as narrative. </p> <p>We also included investigation of heterogeneity between studies, if appropriate:</p> <p> <ul id="CD010981-list-0010"> <li> <p>Age of the study (as the type of platelet component has changed in the last 40 years).</p> </li> <li> <p>Different platelet component doses.</p> </li> <li> <p>Different prophylactic platelet transfusion thresholds.</p> </li> </ul> </p> <p>Four of the six included studies (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), all conducted in the 1970s and 1980s, compared prophylactic platelet transfusions with a platelet count threshold of 20 x 10<sup>9</sup>/L, whilst the two more recent studies, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, used a platelet count threshold of 10 x 10<sup>9</sup>/L for prophylactic platelet transfusions. We did not perform assessment of heterogeneity between studies due to the lack of standardised reporting of outcomes. </p> </section> <section id="CD010981-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <p>We had intended to assess the robustness of our findings by performing the following two sensitivity analyses: </p> <p> <ul id="CD010981-list-0011"> <li> <p>Including only those trials at low risk of bias.</p> </li> <li> <p>Including only those trials in which 20% of participants or less were lost to follow‐up.</p> </li> </ul> </p> <p>All trials were at risk of bias because none of the six included RCTs were blinded.</p> <p>None of the six included trials had more than 20% of participants lost to follow‐up.</p> <p>We therefore did not perform these two sensitivity analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010981-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010981-sec-0050"></div> <section id="CD010981-sec-0051"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>; <a href="./references#CD010981-sec-0155" title="">Characteristics of excluded studies</a>; and <a href="./references#CD010981-sec-0156" title="">Characteristics of ongoing studies</a>. </p> <section id="CD010981-sec-0052"> <h4 class="title">Results of the search</h4> <p>See PRISMA flow diagram (<a href="#CD010981-fig-0001">Figure 1</a>). The original search (conducted January 2002) identified a total of 3196 potentially relevant citations. There were 2380 citations after duplicates were removed, and one review author could exclude 2343 records on the basis of the abstract. The original systematic review identified 37 studies that appeared relevant on the basis of their full text or abstract using the original inclusion/exclusion criteria (<a href="./references#CD010981-bbs2-0214" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub2]">Stanworth 2004</a>). </p> <div class="figure" id="CD010981-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram for original review (1950 to January 2002), updated search (January 2002 to November 2011), and current review (November 2011 to 23 July 2015)" data-id="CD010981-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram for original review (1950 to January 2002), updated search (January 2002 to November 2011), and current review (November 2011 to 23 July 2015) </p> </div> </div> </div> <p>The updated search (conducted November 2011) identified a total of 2622 potentially relevant citations. There were 2054 citations after duplicates were removed, and two review authors could exclude 1865 records on the basis of the abstract. In this review, we retrieved 152 full‐text articles for relevance. Two review authors reviewed these full‐text articles and those from the original review (a total of 189 citations). </p> <p>This search (conducted 23 July 2015) identified a total of 4972 potentially relevant citations. There were 3974 citations after duplicates were removed, and any two of three review authors (LE, GC, CD) could exclude 3951 records on the basis of the abstract. Two review authors (LE, GC) retrieved for relevance and reviewed 23 full‐text articles. </p> <p>The previous systematic review, <a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>, identified five trials that compared therapeutic‐only platelet transfusions versus prophylactic platelet transfusions, three completed trials, <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>, <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>, and <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>, and two ongoing studies, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, which are now included. This search identified two additional studies (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a>). The study by <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> was not identified in the previous systematic review (<a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>), because the study was only published as an abstract, and had not been identified via handsearching conference proceedings in the original review (<a href="./references#CD010981-bbs2-0214" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub2]">Stanworth 2004</a>). The study was identified via an electronic search after it had been added to the database of the Transfusion Evidence Library (<a href="http://www.transfusionevidencelibrary.com" target="_blank">www.transfusionevidencelibrary.com</a>). </p> <p>We identified no studies that compared prophylactic platelet transfusions with placebo.</p> <p>In total, seven studies were assessed and deemed eligible for inclusion (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Findings of the <a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a> have yet to be published. </p> </section> <section id="CD010981-sec-0053"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a> for full details of each study. Seven studies were eligible for inclusion; one of these studies is ongoing (<a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a>). </p> <p>The six remaining RCTs (21 publications) were published between 1978 and 2013. There were 15 secondary citations of included studies (cited as secondary references for the relevant included studies). Three studies were included in the original review (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), and three new studies have been added to this update review (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> was only reported as a short abstract, and no further information was available from the author, therefore we excluded this study from any quantitative analysis (12 participants were randomised, but the numbers in each arm of the study were not stated). <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> was originally published in short abstract form; the author provided a copy of their final unpublished manuscript. Data presented in the review is from both the abstract and unpublished manuscript. </p> <p>See <a href="#CD010981-tbl-0002">Table 1</a> for study characteristics, including number and type of participants, type of intervention, duration of study, type of platelet product, and primary outcome. </p> <div class="table" id="CD010981-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Therapeutic versus prophylactic platelet transfusion studies ‐ characteristics of studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristics of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of platelet product</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcome</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with a haematological malignancy receiving myelosuppressive chemotherapy or undergoing autologous HSCT </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusions were not given if the plt count was &lt; 10 x 10<sup>9</sup>/L vs </p> <p>plt transfusions were given at a threshold plt count of &lt; 10 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median days on study was 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled plt products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occurence of a WHO Grade 2 bleed or above</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with AML or undergoing autologous HSCT for leukaemia in remission, non‐Hodkgin lymphoma, Hodkgin's disease, or myeloma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusions were only given for WHO Grade 2 bleeds or higher vs plt transfusions were given at a threshold plt count of &lt; 10 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When plt count was self sustaining at more than 20 x 10<sup>9</sup>/L for 2 days, or a maximum of 30 days, or at hospital discharge, or treatment failure, death or at study withdrawal, whichever occurred first </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled plt products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of plt transfusions during standardised observation period of 14 days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with amegakaryocytic</p> <p>thrombocytopenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given for clinically significant bleeding and just prior to invasive procedures vs prophylactic plt transfusion given if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equally given single‐donor and random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion give in presence of 5 clinical indicators of bleeding vs prophylactic plt transfusion given if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding outcomes and plt transfusion requirements were reported at 10 months.</p> <p>Mean follow‐up of 19.9 months to 20.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given in presence of haemorrhage vs prophylactic platelet transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with AML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given if clinically significant bleeding or &gt; 50% fall in plts to &lt; 20 x 10<sup>9</sup>/L in previous 24 hours vs prophylactic plt transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AML: acute myeloid leukaemia<br/>HSCT: haematopoietic stem cell transplantation<br/>plt: platelet </p> </div> </div> <section id="CD010981-sec-0054"> <h5 class="title">Design</h5> <p>All six studies were open‐label studies. There were three single‐centre parallel RCTs (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), one factorial RCT (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>), and two multi‐centre parallel RCTs (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> </section> <section id="CD010981-sec-0055"> <h5 class="title">Sample sizes</h5> <p>The number of participants randomised ranged from 12 in <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> to 600 in <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>. </p> </section> <section id="CD010981-sec-0056"> <h5 class="title">Setting</h5> <p>Four studies were conducted in the 1970s and 1980s (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), and two studies were conducted in the mid‐ to late 2000s (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Two studies were conducted in the United States (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), one in Canada (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>), one in the Netherlands (<a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>), one in Germany (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), and one in both Australia and the United Kingdom (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> </section> <section id="CD010981-sec-0057"> <h5 class="title">Participants</h5> <p>The previous systematic review included a total of 99 participants. This review now includes a total of 1195 participants randomised to receive either therapeutic‐only or prophylactic platelet transfusions. Of these 1195 participants, we included only 1186 in the analysis. <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a> excluded two participants because they died from an intracranial haemorrhage on the first day of the study. <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> excluded two participants from analysis as they were lost to follow‐up, and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> excluded four participants from the analysis because they did not receive the allocated intervention, and one was lost to follow‐up. </p> <p>Study populations varied slightly between studies but were fairly comparable. Five of the six studies enrolled adults with a haematological malignancy (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), whilst one study enrolled paediatric patients with acute leukaemia (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>). Three of the six studies only included participants with acute leukaemia (acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL), or both) (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). The three other studies also included people with other haematological disorders who were either thrombocytopenic or expected to become thrombocytopenic for at least five days or who were undergoing an HSCT (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <section id="CD010981-sec-0058"> <h6 class="title">Studies' exclusion criteria</h6> <p>Four of the six studies reported exclusion criteria (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Three of these four studies excluded people with specific types of leukaemia. Two studies excluded people with acute promyelocytic leukaemia (APML) (<a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>), whilst <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> only included people with APML who were in complete remission. Three of the these four studies excluded people with platelet refractoriness (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Two of these four studies excluded participants who were not candidates for aggressive therapy (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>), whereas <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> only included people who were enrolled in specific leukaemia trials or were receiving an autologous HSCT. Two of these four studies excluded participants if they were not expected to have prolonged thrombocytopenia (at least five days with a platelet count ≤ 50 x 10<sup>9</sup>/L) (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). Two of these four studies excluded people with a known history of clinically significant bleeding, a haemostatic or coagulation disorder (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). One of the four studies excluded participants in the autologous HSCT group who had pulmonary or cerebral lesions and participants with light‐chain amyloidosis (<a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). One of these four studies excluded participants who required treatment with regular antiplatelet agents or anticoagulants (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). One of these four studies excluded women who were pregnant (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> </section> </section> <section id="CD010981-sec-0059"> <h5 class="title">Intervention</h5> <p>Four of the six studies (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), all conducted in the 1970s and 1980s, compared prophylactic platelet transfusions with a platelet count threshold of 20 x 10<sup>9</sup>/L versus a therapeutic‐only platelet transfusion regimen (platelet transfusions given for clinically significant bleeding). In two of these four studies, platelet transfusions were also given in the therapeutic arm for specific indications (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). In <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>, platelet transfusions were also given in the therapeutic ("specific indications") arm if there had been a 50% fall in platelets to below 20 x 10<sup>9</sup>/L over the previous 24 hours. In <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, platelet transfusions were also given in the therapeutic arm prior to invasive procedures. The two more recent studies, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, used a platelet count threshold of 10 x 10<sup>9</sup>/L for prophylactic platelet transfusions and gave therapeutic platelet transfusions for clinically relevant bleeding, defined as WHO Grade 2 or higher. <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> specified that platelet transfusions would be given to both groups prior to planned invasive procedures, and could also be given at the physician's discretion (the most common reason was because patients were septic or unwell). <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> specified that prophylactic platelet transfusions would be given to the therapeutic group at a threshold platelet count of 10 x 10<sup>9</sup>/L when there was an increased bleeding risk due to associated coagulopathy, sepsis, or infection. </p> <p>Five of the six studies defined the platelet dose (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), however the platelet dose definition varied between studies. Two studies defined a therapeutic or prophylactic platelet dose as a single adult platelet unit (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). In <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>, the platelet dose was 4 units/m<sup>2</sup>, and in <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> the dose was 4 x 10<sup>11</sup>/unit. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> reported an average dose for the random‐donor group of 5.44 x 10<sup>11</sup> platelets/unit and 4.8 x 10<sup>11</sup> platelets/unit in the single‐donor group. </p> <p>The type of platelet product varied between studies. <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> did not specify the type of platelet product. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> and <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a> used pooled random‐donor platelets. <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> used both apheresis and pooled platelet components. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> specifically set out to compare both single‐donor and blood bank (random‐donor) platelets between the therapeutic‐only and prophylactic arms. </p> </section> <section id="CD010981-sec-0060"> <h5 class="title">Co‐interventions</h5> <p>Two of the six studies reported a red cell transfusion policy (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> transfused participants to maintain a haemoglobin concentration at 80 g/L or higher, whilst <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> used a haemoglobin threshold of 90 g/L in the absence of blood loss due to bleeding. </p> <p>One of the six studies was a factorial study with four treatment arms (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>). Participants were randomised to receive random‐donor versus single‐donor platelet components, as well as a therapeutic‐only versus prophylactic platelet transfusion strategy. </p> <p>None of the studies reported any other co‐interventions.</p> </section> <section id="CD010981-sec-0061"> <h5 class="title">Outcomes</h5> <section id="CD010981-sec-0062"> <h6 class="title">Studies contributing to the main outcomes</h6> <p>See <a href="#CD010981-sec-0074">Effects of interventions</a> for the number of studies that report each review outcome. </p> <p>Three of the six studies reported a primary outcome (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). The primary outcome for <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> was survival, whilst the primary endpoint for <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was the number of platelet transfusions given during the study observation period of 14 days. In contrast, the primary outcome for <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> was the proportion of participants who experienced WHO Grade 2, 3, or 4 bleeding events up to 30 days from randomisation. </p> </section> </section> <section id="CD010981-sec-0063"> <h5 class="title">Funding sources</h5> <p>Four studies reported the funding sources for the trial (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). All sources of funding were either from charitable foundations or government funds. </p> </section> </section> <section id="CD010981-sec-0064"> <h4 class="title">Ongoing studies</h4> <p>This review identified one ongoing study that was eligible for inclusion, the <a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a>. The <a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a> is a feasibility study in adults with myelodysplastic syndrome and severe thrombocytopenia receiving outpatient supportive therapy. The study was due for completion in June 2014, however the study was put on hold due to poor study accrual. Study authors are expected to present their findings later this year. </p> <p>The previous systematic review, <a href="./references#CD010981-bbs2-0212" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD004269. [DOI: 10.1002/14651858.CD004269.pub3]">Estcourt 2012a</a>, identified five potentially relevant trials; three of these have since been excluded because they were studying the wrong intervention (<a href="./references#CD010981-bbs2-0041" title="FranklinIM . Clinical efficacy of platelet transfusions. Within previous version of this Cochrane review. Stanworth 2004. ">Franklin 1995</a>; <a href="./references#CD010981-bbs2-0082" title="LuFQ , WangWM , YuM . Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenic patients. Vox Sanguinis2011;101(S1):310 (P-577). ">Lu 2011</a>; <a href="./references#CD010981-bbs2-0090" title="NCT00180986. Randomized trial of platelet transfusion policies after blood stem cells transplantation in young children: Reduction of number of single platelet concentrate donors per child. http://clinicaltrials.gov/show/NCT00180986. Accessed 5 March 2010. ">NCT00180986</a>), and two are now included in this systematic review (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>See <a href="./references#CD010981-sec-0156" title="">Characteristics of ongoing studies</a> for further details. </p> </section> <section id="CD010981-sec-0065"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD010981-sec-0155" title="">Characteristics of excluded studies</a> for further details. </p> <p> <ul id="CD010981-list-0012"> <li> <p>Twelve studies compared different participant groups: <a href="./references#CD010981-bbs2-0012" title="AndrewM , VeghP , CacoC , KirpalaniH , JefferiesA , OhlssonA , et al. A randomized controlled trial of platelet transfusions in thrombocytopenic premature infants. Journal of Pediatrics1993;123(2):285-91. ">Andrew 1993</a>; <a href="./references#CD010981-bbs2-0014" title="ArnoldDM , CrowtherMA , CookRJ , SigouinC , HeddleNM , MolnarL , et al. Utilization of platelet transfusions in the intensive care unit: Indications, transfusion triggers, and platelet count responses. Transfusion2006;46(8):1286-91. ">Arnold 2006</a>; <a href="./references#CD010981-bbs2-0016" title="BaiCM , XuGX , ZhaoYQ , HanSM , ShanYD . A multi-centre clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae2004;26(4):437-41. ">Bai 2004</a>; <a href="./references#CD010981-bbs2-0039" title="FanningJ , HilgersRD , MurrayKP , BoltK , AughenbaughDM . Conservative management of chemotherapy-induced thrombocytopenia in women with gynecological cancers. Gynecologic Oncology1995;59:191-3. ">Fanning 1995</a>; <a href="./references#CD010981-bbs2-0043" title="GajicO , DzikWH , ToyP . Fresh frozen plasma and platelet transfusion for non-bleeding patients in the intensive care unit: Benefit or harm?Critical Care Medicine2006;35(5 Suppl):S170-3. ">Gajic 2006</a>; <a href="./references#CD010981-bbs2-0044" title="GerdayE , BaerVL , LambertDK , PauDA , Sola-VisnerMC , PysherTJ , et al. Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion2009;49:2034-9. ">Gerday 2009</a>; <a href="./references#CD010981-bbs2-0068" title="JohanssonPI , StensballeJ , RosenbergI , HisløvTL , JørgensenL , SecherNH . Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion2007;47(4):593-8. ">Johansson 2007</a>; <a href="./references#CD010981-bbs2-0069" title="JulmyF , AmmannRA , TaleghaniBM , FontanaS , HirtA , LeibundgutK . Transfusion efficacy of ABO major-mismatched platelets (PLTS) in children is inferior to that of ABO-identical platelets. Transfusion2009;91(1):21-33. ">Julmy 2009</a>; <a href="./references#CD010981-bbs2-0091" title="NCT00699621. Platelet transfusion in acute intracerebral haemorrhage. https://clinicaltrials.gov/ct2/show/NCT00699621. Accessed 18 August 2011. ">NCT00699621</a>; <a href="./references#CD010981-bbs2-0104" title="ReedRL , CiavarellaD , HeimbachDM , BaronL , PavlinE , CountsRB , et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Annals of Surgery1986;203(1):40-8. ">Reed 1986</a>; <a href="./references#CD010981-bbs2-0122" title="SpiessBD , RoystonD , LevyJH , FitchJ , DietrichW , BodyS , et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion2004;44(8):1143-8. ">Speiss 2004</a>; <a href="./references#CD010981-bbs2-0132" title="Vadhan-RajS , KavanaghJJ , FreedmanRS , FolloderJ , CurrieLM , Bueso-RamosC , et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. The Lancet2002;359:2145-52. ">Vadhan‐Raj 2002</a> </p> </li> <li> <p>Sixty‐four studies compared different types of platelet formulations with outcome measures not relevant to the eligibility criteria: <a href="./references#CD010981-bbs2-0008" title="AgliastroRE , De FrancisciG , BonaccorsoR , SpicolaD , ZiinoO , AricoM , et al. Clinical study in pediatric hemato-oncology patients:efficacy of pathogen inactivated platelets versus apheresis platelets. Transfusion2006;46(9S):117A. ">Agliastro 2006</a>; <a href="./references#CD010981-bbs2-0009" title="AkkökCA , BrinchL , LauritzsenGF , SolheimBG , Kjelsden-KraghJ . Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sanguinis2007;93(1):42-8. ">Akkök 2007</a>; <a href="./references#CD010981-bbs2-0010" title="Anderson NA, GrayS , CopplestoneJA , ChanDC , HamonM , PrenticeAG , et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfusion Medicine1997;7:33-9. ">Anderson 1997</a>; <a href="./references#CD010981-bbs2-0013" title="ArnoldDM , HeddleNM , CarruthersJ , KulczyckyM , SigouinC , BlajchmanMA . A randomized crossover trial comparing in-vivo platelet recovery and survival of leukoreduced apheresis and whole blood derived platelets. Transfusion2004;44(supplement):1A. ">Arnold 2004</a>; <a href="./references#CD010981-bbs2-0018" title="BentleyM , TaylorK , KellyC , TaylorD , LeachB , RodwellR , et al. Thrombopoietin derived autologous cryopreserved platelet support for peripheral blood progenitor cell transplantation. In: Haematology Society of Australia and New Zealand Annual Scientific Meeting. Perth, 2000. ">Bentley 2000</a>; <a href="./references#CD010981-bbs2-0020" title="BlumbergN , HealJM , RoweJM . Platelet transfusion and clinical outcome in acute leukemia in adults. Transfusion2002;42(9S):5S. ">Blumberg 2002</a>; <a href="./references#CD010981-bbs2-0021" title="BlundellEL , PamphilonDH , FraserID , KagenL , MenitoveJE , AsterRH , et al. A prospective randomised study of platelet concentrates irradiated with ultraviolet (UV)-B light in patients with high grade haematological malignancy. Blood1992;80(10):215A. BlundellEL , PamphilonDH , FraserID , MenitoveJE , GreeenwaltTJ , SnyderEL , et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion1996;36(4):296-302. ">Blundell 1996</a>; <a href="./references#CD010981-bbs2-0025" title="CarrR , HuttonJL , JenkinsJA , LucasGF , AmphlettNW . Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. British Journal of Haematology1990;75:408-13. ">Carr 1990</a>; <a href="./references#CD010981-bbs2-0029" title="CoubanS , CarruthersJ , AndreouP , KlamaLN , BarrR , KeltonJG , et al. Platelet transfusions in children: results of a randomised prospective cross-over trial of plasma removal and a prospective audit of WBC reduction. Transfusion2002;42:753-8. ">Couban 2002</a>; <a href="./references#CD010981-bbs2-0031" title="deWildt-EggenJ , NautaS , SchrijverJG , vanMarwijkKM , BinsM , vanProoijenHC , et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion2000;40(4):398-403. ">de Wildt‐Eggen 2000</a>; <a href="./references#CD010981-bbs2-0032" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064-72. ">Diedrich 2005</a>; <a href="./references#CD010981-bbs2-0033" title="DiedrichB , RingdenO , WatzE , ShanwellA . A randomised study of buffy coat platelets in platelet additive solution 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic cell transplant recipients. Vox Sanguinis2009;97(3):254-9. DiedrichB , WatzE , RingdenO , ShanwellA . A randomized study in allogeneic haematopoietic stem cell transplant recipients comparing prophylactic transfusion of buffy coat platelets stored for 1-5 vs. 6-7 days. Vox Sanguinis2008;95(Supp 1):Abstract. ">Diedrich 2009</a>; <a href="./references#CD010981-bbs2-0034" title="DumontLJ , DumontDF , UngerZM , SiegelA , SzczepiorkowskiZM , CorsonJS , et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet(plt) recoveries and survivals of 7-day-stored plt-rich plasma and buffy coat plts from the same subjects. Transfusion 51;6:1241-8. ">Dumont 2011</a>; <a href="./references#CD010981-bbs2-0041" title="FranklinIM . Clinical efficacy of platelet transfusions. Within previous version of this Cochrane review. Stanworth 2004. ">Franklin 1995</a>; <a href="./references#CD010981-bbs2-0046" title="GmürJ , vonFeltenA , OsterwalderB , HoneggerH , HermannA , SauterC , et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood1983;62(2):473-9. ">Gmür 1983</a>; <a href="./references#CD010981-bbs2-0048" title="GoodnoughLT , KuterDJ , McCulloughJ , SlichterSJ , DiPersioJ , RomoJ , et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood2001;98(5):1346-51. ">Goodnough 2001</a>; <a href="./references#CD010981-bbs2-0051" title="GoodrichR , FolluaG , RobertsT . Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion2008;48(S2):20A. ">Goodrich 2008</a>; <a href="./references#CD010981-bbs2-0053" title="GurkanE , PatahPA , SalibaRM , RamosCA , AndersonBS , ChamplinR , et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation2007;40(5):461-4. ">Gurkan 2007</a>; <a href="./references#CD010981-bbs2-0055" title="HarrupRA , KennedyJT , KissJ , DanielsB . Randomised blinded comparison of buffy coat plasma or T-sol supported platelet transfusions. In: Haematology Society of Australia and New Zealand Annual Scientific Meeting. Hobart; Tasmania, 1999. ">Harrup 1999</a>; <a href="./references#CD010981-bbs2-0056" title="HealJ , KemmotsuN , RoweJ , BlumbergN . A survival advantage in leukaemics receiving ABO identical platelets. Blood1991;78:349a. HealJ , RoweJ , BlumbergN . The importance of ABO identical platelet transfusions. Blood1991;78:348a. HealJ , RoweJ , McMicanA , FinkeK , BlumbergN . A randomised trial of ABO identical versus ABO unmatched platelet transfusions. Blood1989;74(7 Supp 1):215a. HealJM , RoweJM , McMicanA , MaselD , FinkeC , BlumbergN . The role of ABO matching in platelet transfusion. European Journal of Haematology1993;50:110-7. ">Heal 1993</a>; <a href="./references#CD010981-bbs2-0058" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia [American Society of Hematology 35th Annual Meeting]. Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143-9. ">Heckman 1997</a>; <a href="./references#CD010981-bbs2-0059" title="HeddleNM , KlamaL , SingerJ , RichardsC , FedakP , WalkerI , et al. The role of the plasma from platelet concentrates in transfusion reactions. The New England Journal of Medicine1994;331(10):625-8. ">Heddle 1994</a>; <a href="./references#CD010981-bbs2-0060" title="HeddleNM , KlamaL , MeyerR , WalkerI , BoshkovL , RobertsR , et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion1999;39(3):231-8. ">Heddle 1999</a>; <a href="./references#CD010981-bbs2-0061" title="HeddleNM , BlajchmanMA , MeyerRM , LiptonJH , WalkerIR , Sher GD et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion2002;42(5):556-66. ">Heddle 2002</a>; <a href="./references#CD010981-bbs2-0063" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564-73. HeddleNM , WuC , VassalloR , CareyP , ArnoldD , LozanoM , et al. Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion2011;51:2304-10. NCT00420914. Strategies for Transfusion of Platelets (SToP). http://clinicaltrials.gov/show/NCT00420914 Accessed 15 September 2009. ">Heddle 2009</a>; <a href="./references#CD010981-bbs2-0064" title="HigbyDJ , CohenE , HollandJF , SinksL . The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion1974;14:440-5. ">Higby 1974</a><a href="./references#CD010981-bbs2-0066" title="ISRCTN49080246. Platelet process improvement project. http://www.controlled-trials.com/ISRCTN49080246. Accessed 19 August 2011. ">ISRCTN49080246</a>; <a href="./references#CD010981-bbs2-0070" title="KakaiyaRM , HezzeyAJ , BoveJR , KatzAJ , GencoPV , BuchholzDH , et al. Alloimmunization following apheresis platelets vs. pooled platelet concentrates. A prospective randomized study. Transfusion1981;21(5):600. ">Kakaiya 1981</a>; <a href="./references#CD010981-bbs2-0071" title="KerkhoffsJH , NovotnyVM , Te BoekhorstPA , SchipperusMR , ZwagingaJJ , vanPampusI , et al. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. Transfusion2009;49(s3):2A. KerkhoffsJL , vanPuttenWL , NovotnyVM , Te BoekhorstPA , SchipperusMR , ZwagingaJJ , et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology2010;150(2):209-17. ">Kerkhoffs 2010</a>; <a href="./references#CD010981-bbs2-0072" title="AckermanSJ , KlumppTR , GuzmanGI , HermanJH , GaughanJP , BleeckerGC , et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion2000;40(12):1457-62. HermanJH , KlumppTR , ChristmanRA , RussoRR , GoldbergSL , ManganKF . The effect of platelet dose on the outcome of prophylactic platelet transfusion. In: Proceedings of the 48th Annual Meeting of the American Association of Blood Banks. 1995:35. KlumppTR , HermanJH , ChristmanRA , RussoRR , GoldbergSL , MacdonaldJS , et al. The effect of platelet dose on the interval between platelet transfusions in patients undergoing bone marrow or peripheral blood stem cell transplantation. In: Proceedings of the American Society of Clinical Oncology. Los Angeles, 1995    :536. KlumppTR , HermanJH , GaughanJP , RussoRR , ChristmanRA , GoldbergSL , et al. Clinical consequences of alterations in platelet dose: a prospective, randomized, double-blind trial. Transfusion1999;39:674-81. ">Klumpp 1999</a>; <a href="./references#CD010981-bbs2-0073" title="LapierreV , BenhamouE , TramalloniD , BraultP , Valteau-CouanetD , DucourtieuxM , et al. A randomised trial of platelet transfusion policies after blood stem cell transplantation in young children: reduction of number of single platelet concentrate donors per child. In: European Group for Blood and Bone Marrow Transplantation Annual Congress. Istanbul, Turkey, 2003:P756. ">Lapierre 2003</a>; <a href="./references#CD010981-bbs2-0075" title="LeachMF , FairweatherRB , AubuchonJP . Use of warmed single donor platelets in autologous bone marrow transplant patients. Transfusion1991;31(Suppl):20S. ">Leach 1991</a>; <a href="./references#CD010981-bbs2-0076" title="LeeEJ , SchifferCA . ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion1989;29(5):384-9. ">Lee 1989</a>; <a href="./references#CD010981-bbs2-0080" title="LozanoM , KnutsonF , TardivelR , CidJ , MaymóR , LöfH , et al. Frequency of prophylactic transfusion failure: a novel outcome to evaluate platelet components stored more than 5 days. Transfusion2010;50(Supp 2):25A-6A. ">Lozano 2010</a>; <a href="./references#CD010981-bbs2-0081" title="LozanoM , KnutsonF , TardivelR , CidJ , MaymóRM , LöfH , et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotsalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. British Journal of Haematology2011;153(3):393-401. ">Lozano 2011</a>; <a href="./references#CD010981-bbs2-0082" title="LuFQ , WangWM , YuM . Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenic patients. Vox Sanguinis2011;101(S1):310 (P-577). ">Lu 2011</a>; <a href="./references#CD010981-bbs2-0084" title="BenjaminRJ , GoodnoughLT , Lopez-PerezI , StraussR , McCulloughJ , SlichterS , et al. Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments. However fresh platelets result in superior hemostasis: results of the SPRINT trial. Transfusion2003;43(9S):9A. GoodnoughLT , McCulloughJ , SlichterS , StraussR , LinJ , ConlanM . A platelet transfusion threshold of 20 x 109/L compared to 10 x 109/L is associated with increased pre-transfusion bleeding and increased platelet transfusions: results of the SPRINT study. Transfusion2002;42(9S):17S. KluterH , ChapuisB , CazenaveJ , HastkaJ , BerisP , DufourP , et al. Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sanguinis2002;83(Suppl 1):110a. McCulloughJ , VesoleDH , BenjaminRJ , SlichterSJ , PinedaA , SynderE , et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood2004;104(5):1534-41. MurphyS , SlichterS , McCulloughJ , StraussR , WoodL , LinJ , et al. INTERCEPT platelets are hemostatically as effective as conventional platelet in the prophylaxis and treatment of bleeding: results of the SPRINT trial. Vox Sanguinis2002;83(109):Abstract. MurphyS , SynderE , CableR , SlichterSJ , StraussRG , McCulloughJ , et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion2006;46(1):24-33. SlichterSJ , MurphyS , BuchholzD , LinJ , CorashL , ConlanM . INTERCEPT platelets (plts) and conventional plts provide comparable hemostatic response in thrombocytopenic patients: the SPRINT trial. Blood 20022002;11(Pt 2):141b. StraussRG , SlichterS , Lopez-PlazaI , GoodnoughLT , McCulloughJ , LinJ , et al. Intercept platelets exhibit immunological refractoriness comparable to conventional platelets. Haematologica2004;89(Suppl 1):Various. ">McCullough 2004</a>; <a href="./references#CD010981-bbs2-0086" title="MesserschmidtGL , MakuchR , AppelbaumF , UngerleiderRS , AbramsR , O'DonnellJ , et al. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients. Cancer1988;62(4):795-801. ">Messerschmidt 1988</a>; <a href="./references#CD010981-bbs2-0087" title="The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion2010;50:2362-75. ">Mirasol 2010</a>; <a href="./references#CD010981-bbs2-0088" title="MurphyMF , MetcalfeP , ThomasH , EveJ , OrdJ , ListerTA , et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. British Journal of Haematology1986;62:529-34. ">Murphy 1986</a>; <a href="./references#CD010981-bbs2-0090" title="NCT00180986. Randomized trial of platelet transfusion policies after blood stem cells transplantation in young children: Reduction of number of single platelet concentrate donors per child. http://clinicaltrials.gov/show/NCT00180986. Accessed 5 March 2010. ">NCT00180986</a>; <a href="./references#CD010981-bbs2-0094" title="OksanenK , KekomakiR , RuutuT , KoskimiesS , MyllylaG . Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components: A randomized trial. Transfusion1991;31:588-94. ">Oksanen 1991</a>; <a href="./references#CD010981-bbs2-0095" title="OksanenK , EbelingF , KekomäkiR , ElonenE , SahlstedtL , VolinL , et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sanguinis1994;67(4):356-61. ">Oksanen 1994</a>; <a href="./references#CD010981-bbs2-0097" title="PamphilonDH . Comparative clinical studies of platelet concentrates: effects on clinical outcome and the use of healthcare resources. NBS Platelet Study Group. Transfusion Science1996;17(3):343-6. ">Pamphilon 1996</a>; <a href="./references#CD010981-bbs2-0103" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135-42. FinazziG . The platelet transfusion trigger trial (PTTT): a multivariate analysis of risk factors for major bleeding in acute myeloid leukemia (AML) [abstract]. Thrombosis and Haemostasis1997;Supp:768-769. GIMMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at 10 versus 20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903-11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870-5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530-7. ">Rebulla 1997</a>; <a href="./references#CD010981-bbs2-0106" title="RoyAJ , JaffeN , DjerassiI . Prophylactic platelet transfusion in children with acute leukemia: A dose response study. Transfusion1973;13(5):283-90. ">Roy 1973</a>; <a href="./references#CD010981-bbs2-0110" title="SchifferCA , DutcherJP , AisnerJ , HoggeD , WiernikPH , ReillyJP , et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood1983;62:815-20. ">Schiffer 1983</a>; <a href="./references#CD010981-bbs2-0111" title="SensebeL , GiraudeauB , BardiauxL , DeconninckE , IfrahN , Bidet M-L, et al. Increasing dose improves the platelet transfusions: results of a prospective multicentre randomised study. Blood2002;100:(Abstract 2789) 708a. SensebeL , GiraudeauB , BaridauxL , DeconinckE , SchmidtA , BidetML , et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood2004;105:862-4. ">Sensebe 2004</a>; <a href="./references#CD010981-bbs2-0112" title="ShanwellA , LarssonS , AschanJ , RingdenO . A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients. European Journal of Haematology1992;49(2):77-81. ">Shanwell 1992</a>; <a href="./references#CD010981-bbs2-0115" title="SingerJ , AliAM , WarkentinTE , BlajchmanMA , KeltonJG . A prospective randomized study of platelet support in leukemic patients. Transfusion1988;72(5 Supp):285A. ">Singer 1988</a>; <a href="./references#CD010981-bbs2-0116" title="SintnicolaasK , vanMarwijk KooijM , vanProoijen HC , vanDijkBA , vanPuttenWL , ClaasFH , et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study. Blood1995;85:824-8. ">Sintnicolaas 1995</a>; <a href="./references#CD010981-bbs2-0118" title="SlichterSJ , RaifeTJ , DavisK , RheinschmidtM , BuchholzDH , CorashL , et al. Platelets photochemically treated with amotsalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion2006;46(5):731-40. ">Slichter 2006</a>; <a href="./references#CD010981-bbs2-0120" title="JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A-20A. JosephsonCD , GrangerS , AssmannSF , CastillejoMI , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia [         ]. Blood2012;120(4):748-60. NCT00128713. Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713. Accessed 16 April 2010. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600-13. SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78-84. ">Slichter 2010</a>; <a href="./references#CD010981-bbs2-0123" title="SteffensI , HarrisonJF , TaylorCPF . A dose response study of platelet transfusion: comparison between triple dose apheresis platelet transfusion and three split standard transfusions. Haematologica2002;87(Suppl 1):Various. ">Steffens 2002</a>; <a href="./references#CD010981-bbs2-0126" title="StrindbergJ , BerlinG . Transfusion of platelet concentrates - clinical evaluation of two preparations. European Journal of Haematology1996;57(4):307-11. ">Strindberg 1996</a>; <a href="./references#CD010981-bbs2-0127" title="SweeneyJD , KouttabNM , PennCL , McHughKE , NelsonEJ , OblonDJ . A comparison of prestorage WBC-reduced whole blood derived platelets in autologous progenitor cell transplant. Transfusion2000;40(7):794-800. ">Sweeney 2000</a>; <a href="./references#CD010981-bbs2-0129" title="TinmouthA , KotchetkovaN , TomlinsonG , CrumpM , BrandweinJ , TannockI , et al. A randomised phase II trial of low dose and standard dose platelet transfusions during induction therapy for acute leukemia or autologous stem cell transplantation. Vox Sanguinis2002;83(Suppl 1):8. TinmouthA , TannockIF , CrumpM , TomlinsonG , BrandweinJ , MindenM , et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor transplant and patients with acute leukaemia: a randomized controlled trial with a sequential Bayesian design. Transfusion Medicine2004;44:1711-9. ">Tinmouth 2004</a>; <a href="./references#CD010981-bbs2-0131" title="EnrightH , DavisK , GernsheimerT , McCulloughJJ , WoodsonR , SlichterSJ . Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion2003;43(11):1545-52. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine1997;337:1861-70. ">TRAP 1997</a>; <a href="./references#CD010981-bbs2-0133" title="vanMarwijk KooyM , vanProoijenHC , MoesM , Bosma-StantsI , AkkermanJW . Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood1991;77:201-5. ">van Marwijk Kooy 1991</a>; <a href="./references#CD010981-bbs2-0134" title="CazenaveJP , DavisK , CorashL . Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Seminars in Hematology2001;38(4 Supp 11):46-54. CazenaveJP , vanRhenenD , GullikssonH , PamphilonD , LjungmanP , DavisK , et al. INTERCEPT buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: the EUROSPRITE trial. Transfusion Clinique et Biologique2001;8(Supp 1):Various. LjungmanP , vanRhenenD , PamphilonD , MetzelP , MarblieS , LinJ , et al. Results of the EUROSPRITE phase III trial: INTERCEPT buffy coat platelet concentrates (IPC) provide effective hemostasis for thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique2001;8(Supp 1):100s. PamphilonD , BuchholzDH , CazenaveJP , ConlanM , CorashL , DavisK , et al. The EUROSPRITE phase III trial of INTERCEPT buffy coat platelet concentrates (IPC) demonstrates IPC are safe when transfused to thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique2001;8(Supp 1):100-1s. vanRhenenD , GullikssonH , CazenaveJP , PamphilonD , LjungmanP , KluterH , et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood2003;101(6):2426-33. ">van Rhenen 2003</a>; <a href="./references#CD010981-bbs2-0140" title="WangSE , LaraPN , LeeOA , ReedJ , WangLR , PalmerP , et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. American Journal of Hematology2002;70(3):191-4. ">Wang 2002</a>; <a href="./references#CD010981-bbs2-0143" title="WilliamsonLM , WimperisJZ , WilliamsonP , CopplestoneJA , GooiHC , MorgensternGR , et al. Bedside filtration of blood products in the prevention of HLA alloimmunization: A prospective randomized study. Alloimmunization Study Group. Blood1994;83:3028-35. ">Williamson 1994</a>; <a href="./references#CD010981-bbs2-0147" title="ZhaoSM , ChengXL , HuJ , XiangGC , ZhangJS , LiRQ . Clinical assessment of preventing febrile nonhemolytic transfusion reaction by leucocyte depleted blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi2002;10(6):568-70. ">Zhao 2002</a>; <a href="./references#CD010981-bbs2-0148" title="ZumbergMS , delRosarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569-76. ZumbergMS , delRosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold. In: Proceedings of the American Society of Clinical Oncology. San Francisco, 2001:20. ">Zumberg 2002</a> </p> </li> <li> <p>Three citations were guidelines: <a href="./references#CD010981-bbs2-0040" title="FolleaG . Homologous platelet concentrates: products available and utilisation rules in oncology and haematology. Hematologie2004;10(3):233-44. ">Follea 2004</a>; <a href="./references#CD010981-bbs2-0109" title="SamamaCM , DjoudiR , LecompteT , NathanDN , SchvedJF . Perioperative platelet transfusion: recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Canadian Journal of Anaesthesia2005;52(1):30-7. SamamaCM , DjoudiR , LecompteT , NathanN , SchvedJF . Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiologica2006;72(6):447-52. ">Samama 2005</a>; <a href="./references#CD010981-bbs2-0130" title="TosettoA , BalduiniCL , CattaneoM , De CandiaE , MarianiG , MolmanAC , et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research2009;125(5):e13-8. ">Tosetto 2009</a> </p> </li> <li> <p>One citation was an audit: <a href="./references#CD010981-bbs2-0100" title="QureshiH , LoweD , DobsonP , Grant-CaseyJ , ParrisE , DaltonD , et al. National comparative audit of the use of platelet transfusions in the UK. Transfusion Clinique Et Biologique2007;14(6):509-13. ">Qureshi 2007</a> </p> </li> <li> <p>One study had fewer than 80% of participants with a haematological disorder: <a href="./references#CD010981-bbs2-0065" title="HoqueMM , RahmanM , RahmanSM , HabibullahMM , FarukiMA , RahmanKH , et al. Post-transfusion increment of platelet count in thrombocytopenic patients treated with platelet concentrates. Mymensingh Medical Journal2013;22(1):64-68. ">Hoque 2013</a> </p> </li> <li> <p>Thirty‐six citations were reviews (including three systematic reviews): <a href="./references#CD010981-bbs2-0011" title="AndreuG , VasseJ , TardivelR , SemanaG . Platelet transfusion: products, indications, dose, threshold and efficacy. Transfusion Clinique Et Biologique2009;16(2):118-33. ">Andreu 2009</a>; <a href="./references#CD010981-bbs2-0015" title="AvvisatiG , TirindelliMC , AnnibaliO . Thrombocytopenia and hemorrhagic risk in cancer patients. Critical Reviews in Oncology/Hematology2003;48(Suppl 1):S13-6. ">Avvisati 2003</a>; <a href="./references#CD010981-bbs2-0017" title="BenjaminRJ , AndersonKC . What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?Critical Reviews in Oncology/Hematology2002;42(2):163-71. ">Benjamin 2002</a>; <a href="./references#CD010981-bbs2-0019" title="BlajchmanMA , SlichterSJ , HeddleNM , MurphyMF . New strategies for the optimal use of platelet transfusions. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2008;2008:198-204. ">Blajchman 2008</a>; <a href="./references#CD010981-bbs2-0022" title="BuhrkuhlDC . An update on platelet transfusion in hematooncology supportive care. Transfusion2010;50(10):2266-76. ">Buhrkuhl 2010</a>; <a href="./references#CD010981-bbs2-0026" title="CasbardAC , WilliamsonLM , MurphyMF , RegeK , JohnsonT . The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia2004;59(6):550-8. ">Casbard 2004</a>; <a href="./references#CD010981-bbs2-0028" title="CidJ , LozanoM . Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion2007;47:464-70. ">Cid 2007</a>; <a href="./references#CD010981-bbs2-0035" title="DzikWH . Predicting hemorrhage using preoperative coagulation screening assays. Current Hematology Reports2004;3(5):324-30. ">Dzik 2004</a>; <a href="./references#CD010981-bbs2-0049" title="GoodnoughLT , DiPersioJFD . Issues in the management of cancer-related thrombocytopenia. Oncology2002;16(11):1558-67. ">Goodnough 2002</a>; <a href="./references#CD010981-bbs2-0050" title="GoodnoughLT . Risks of blood transfusion. Anesthesiology Clinics of North America2005;23(2):241-52. ">Goodnough 2005</a>; <a href="./references#CD010981-bbs2-0057" title="HealJM , BlumbergN . Optimizing platelet transfusion therapy. Blood Reviews2004;18(3):149-65. ">Heal 2004</a>; <a href="./references#CD010981-bbs2-0062" title="HeddleNM , CookRJ , WebertKE , SigouinC , RebullaP . Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion2003;43:742-52. ">Heddle 2003</a>; <a href="./references#CD010981-bbs2-0067" title="JelicS , RadulovicS . Chemotherapy-associated thrombocytopenia current and emerging management strategies. American Journal of Cancer2006;5(6):371-82. ">Jelic 2006</a>; <a href="./references#CD010981-bbs2-0077" title="LeviMM , VinkR , de Jonge, E. Management of bleeding disorders by prohemostatic therapy. International Journal of Hematology2002;76(Suppl 2):139-44. ">Levi 2002</a>; <a href="./references#CD010981-bbs2-0078" title="LordkipanidzeM , DiodatiJG , PharandC . Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacology &amp; Therapeutics2009;123(2):178-86. ">Lordkipanidze 2009</a>; <a href="./references#CD010981-bbs2-0079" title="LozanoM , CidJ . The clinical implications of platelet transfusions associated with ABO or Rh[D) incompatibility. Transfusion Medicine Reviews2003;17(1):57-68. ">Lozano 2003</a>; <a href="./references#CD010981-bbs2-0083" title="MartelN , WellsPS . A meta-analysis to determine the risk of heparin induced thrombocytopenia (HIT) and isolated thrombocytopenia in prophylaxis studies comparing unfractioneted heparin (UFH) and low molecular weight heparin (LMWH). Blood2004;104(11):708a-9a. ">Martel 2004</a>; <a href="./references#CD010981-bbs2-0085" title="McNicolA , IsraelsSJ . Platelets and platelet therapy. Journal of Pharmacological Sciences2003;93(4):381-96. ">McNicol 2003</a>; <a href="./references#CD010981-bbs2-0098" title="ParamoJA , LecumberriR , HernandezM , RochaE . Pharmacological alternatives to blood transfusion: what is new about?Medicina Clinica2004;122(6):231-6. ">Paramo 2004</a>; <a href="./references#CD010981-bbs2-0099" title="PoonMC . Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?Current Hematology Reports2003;2(2):139-47. ">Poon 2003</a>; <a href="./references#CD010981-bbs2-0101" title="RabinowitzI . Dose of prophylactic platelet transfusions did not affect bleeding incidence or severity. ACP Journal Club2010;152(6):11. ">Rabinowitz 2010</a>; <a href="./references#CD010981-bbs2-0102" title="RaymentR , Brunskill, SJ, StanworthS , SoothillPW , RobertsDJ , MurphyMF . Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD004226. [DOI: 10.1002/14651858.CD004226.pub2]">Rayment 2005</a>; <a href="./references#CD010981-bbs2-0105" title="RobertsIAG , MurrayNA . Thrombocytopenia in the newborn. Current Opinion in Pediatrics2003;15(1):17-23. ">Roberts 2003</a>; <a href="./references#CD010981-bbs2-0108" title="SakakuraM , WadaH . Prevention of hemorrhage occurring in patients with leukemia. Zassh (Nippon-Naika-Gakkai-Zasshi)2003;92(6):1025-9. ">Sakakura 2003</a>; <a href="./references#CD010981-bbs2-0113" title="ShehataN , TinmouthA , NaglieG , FreedmanJ , WilsonK . ABO-identical versus non-identical platelet transfusion: a systematic review. Transfusion2009;49:2442-53. ">Shehata 2009</a>; <a href="./references#CD010981-bbs2-0114" title="Shen Y-MP, FrenkelEP . Acquired platelet dysfunction. Hematology/Oncology Clinics of North America2007;21(4):647-61. ">Shen 2007</a>; <a href="./references#CD010981-bbs2-0117" title="SlichterSJ . Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews2004;18(3):153-67. ">Slichter 2004</a>; <a href="./references#CD010981-bbs2-0119" title="SlichterSJ . Evidence-based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology2007;2007:172-8. ">Slichter 2007</a>; <a href="./references#CD010981-bbs2-0121" title="SosaMEB . Alloimmune thrombocytopenia in the fetus: current management theories. The Journal of Perinatal &amp; Neonatal Nursing2003;17(3):181-9. ">Sosa 2003</a>; <a href="./references#CD010981-bbs2-0124" title="StraussRG . Low-dose prophylactic platelet transfusions: Time for further study, but too early for routine clinical practice. Transfusion2004;44(12):1680-2. ">Strauss 2004</a>; <a href="./references#CD010981-bbs2-0125" title="StraussRG . Pretransfusion trigger platelet counts and dose for prophylactic platelet transfusions. Current Opinion in Hematology2005;12(6):499-502. ">Strauss 2005</a>; <a href="./references#CD010981-bbs2-0128" title="TinmouthAT , FreedmanJ . Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfusion Medicine Reviews2003;17(3):181-93. ">Tinmouth 2003</a>; <a href="./references#CD010981-bbs2-0139" title="WandtH . Indication for platelet transfusion in patients with haematological disease: less is more. [German] [         ]. Deutsche Medizinische Wochenschrift     2010;135(38):1877-9. ">Wandt 2010</a>; <a href="./references#CD010981-bbs2-0141" title="WangXQ . Using evidence-based guideline for prophylactic platelet transfusion in patient with myelodysplastic syndrome. Chinese Journal of Evidence-Based Medicine2005;5(6):482-4. ">Wang 2005</a>; <a href="./references#CD010981-bbs2-0144" title="WoodardP , LubinB , WaltersCMC . New approaches to hematopoietic cell transplantation for hematological diseases in children. Pediatric Clinics of North America2002;49(5):989-1007. ">Woodard 2002</a>; <a href="./references#CD010981-bbs2-0146" title="ZellerMP , Al-HabsiaKS , HeddleNM . Prophylactic platelet transfusions: should they be a treatment of the past?Current Opinion in Hematology2014;21(6):521-7. ">Zeller 2014</a> </p> </li> <li> <p>Twenty‐five studies were not RCTs: <a href="./references#CD010981-bbs2-0007" title="AderkaD , PraffG , SantoM , WeinbergerA , PinkhasJ . Bleeding due to thrombocytopenia in acute leukaemias and reevaluation of the prophylactic platelet transfusion policy. American Journal of the Medical Sciences1986;291:147-51. ">Aderka 1986</a>; <a href="./references#CD010981-bbs2-0023" title="CallowCR , SwindellR , RandallW , ChopraR . The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. British Journal of Haematology2002;118:677-82. ">Callow 2002</a>; <a href="./references#CD010981-bbs2-0024" title="CameronB , RockG , OlbergB , NeurathD . Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion2007;47(2):206-11. ">Cameron 2007</a>; <a href="./references#CD010981-bbs2-0027" title="ChaouiD , ChakrounT , RobertF , RioB , BelhocineR , LegrandO , et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion2005;45(5):766-72. ">Chaoui 2005</a>; <a href="./references#CD010981-bbs2-0030" title="DecaudinD , VantelonJM , BourhisJH , FaraceF , BonnetML , GuillierM , et al. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Bone Marrow Transplantation2004;34(12):1089-93. ">Decaudin 2004</a>; <a href="./references#CD010981-bbs2-0036" title="EderAF , KennedyJM , DyBA , NotariEP , WeissJW , FangCT , et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross Experience (2004-2006). Transfusion2007;47(7):1134-42. ">Eder 2007</a>; <a href="./references#CD010981-bbs2-0037" title="EltingLS , MartinCG , KurtinDJ , CantorSB , RubensteinEB , RodirguezS , et al. The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer2002;94(12):3252-62. ">Elting 2002</a>; <a href="./references#CD010981-bbs2-0038" title="EltingLS , CantorSB , MartinCG , HamblinL , KurtinD , RiveraE , et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer2003;97(6):1541-50. ">Elting 2003</a>; <a href="./references#CD010981-bbs2-0042" title="FriedmannAM , SengulH , LehmannH , SchwartzC , GoodmanS . Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients?Transfusion Medicine Reviews2002;16:34-45. ">Friedmann 2002</a>; <a href="./references#CD010981-bbs2-0045" title="Gil-FernandezJJ , AlegreA , Fernandez-VillaltaMJ , PinillaI , Gomez GarciaV , MartinezC , et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplantation1996;18:931-5. ">Gil‐Fernandez 1996</a>; <a href="./references#CD010981-bbs2-0047" title="GmürJ , BurgerJ , SchanzU , FehrJ , SchaffnerA . Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. The Lancet1991;338:1223-6. ">Gmür 1991</a>; <a href="./references#CD010981-bbs2-0052" title="GreenoE , McCulloughJ , WeisdorfD . Platelet utilisation and the transfusion trigger: A prospective analysis. Transfusion2007;72(2):201-5. ">Greeno 2007</a>; <a href="./references#CD010981-bbs2-0054" title="HardanI , SoferO , ShpilbergO , Ra'ananiP , Ben-BassatI . Safety of stringent prophylactic platelet transfusion (PT) policy for lymphoma patients treated by high dose chemotherapy (HDC) and autologous stem cell support [20th Annual Meeting of the European Group for Bone Marrow Transplantation and 10th Meeting of the Nurses Group]. Bone Marrow Transplant1994;14(Supplement):Abstract 330. ">Hardan 1994</a>; <a href="./references#CD010981-bbs2-0074" title="LawrenceJB , YomtovianRA , HammonsT , MasarikSR , ChongkolwatanaV , CregarRJ , et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leukemia &amp; Lymphoma2001;41:67-76. ">Lawrence 2001</a>; <a href="./references#CD010981-bbs2-0089" title="Navarro J-T, Hernandez J-A, Ribera J-M, Sancho J-M, OriolA , PujolM , et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/mL. Haematologica1998;83:998-1000. ">Navarro 1998</a>; <a href="./references#CD010981-bbs2-0092" title="NevoS , FullerAK , BorinskyME , VogelsangGB . Acute bleeding complications in patients after haematopoietic stem cell transplantation triggers of 10 x 109 and 20 x 109 per L. Transfusion2007;47:801-12. ">Nevo 2007</a>; <a href="./references#CD010981-bbs2-0093" title="NorolF , BierlingP , Roudot-ThoravalF , Ferrer Le CoeurF , RieuxC , LavauxA , et al. Platelet transfusion: a dose response study. Blood1998;92:1448-53. ">Norol 1998</a>; <a href="./references#CD010981-bbs2-0096" title="PaananenP , ArolaMO , PelliniemiTT , SalmiTT , LähteenmäkiPM . Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. Journal of Pediatric Haematology/Oncology2009;31(10):745-9. ">Paananen 2009</a>; <a href="./references#CD010981-bbs2-0107" title="SagmeisterM , OecL , GmürJ . A restrictive platelet transfusion policy allowing long term support of outpatients with severe aplastic anaemia. Blood1999;93:3124-6. ">Sagmeister 1999</a>; <a href="./references#CD010981-bbs2-0135" title="VermaA , PandeyP , KhetanD , ChaudharyR . Platelet transfusions in clinical practice at a multidisciplinary hospital in North India. Transfusion and Apheresis Science2008;39(1):29-35. ">Verma 2008</a>; <a href="./references#CD010981-bbs2-0136" title="WandtH , FrankM , EhningerG , SchneiderC , BrackN , DaoudA , et al. Safety and cost effectiveness of a 10 x 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood1998;91:3601-6. WandtH , FrankM , LinkH , SchneiderC , BrackN , DaoudA , et al. The 10/NL trigger for prophylactic platelet transfusion in AML: a prospective comparative multicenter study. Annals of Hematology1995;70(Suppl 1):A140. ">Wandt 1998</a>; <a href="./references#CD010981-bbs2-0137" title="WandtH , FrankM , Schaefer-EckartK , WilhelmM . Routine prophylactic platelet transfusions are not necessary in patients with acute myeloid leukaemia. A therapeutic transfusion strategy is safe. Blood2005;106(11):Abstract. WandtH , ReinelH , Schaefer-EckartK , WilhelmiM , BirkmannJ , GallmeierWM . New strategy for platelet transfusion for patients with acute myeloid leukaemia: routine prophylactic transfusion replaced by therapeutic transfusion. Blood2002;100(Abstract 2782):706a. ">Wandt 2005</a>; <a href="./references#CD010981-bbs2-0138" title="WandtH , Schaefer-EckartK , FrankM , BirkmannJ , WilhelmM . A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant2006;37(4):387-92. ">Wandt 2006</a>; <a href="./references#CD010981-bbs2-0142" title="WeigandK , EnckeJ , MeyerFJ , HinkelUP , MunderM , StremmelW , et al. Low levels of prothrombin (INR) and platelets do not increase the risk of significant bleeding when placing central venous catheters. Medizinische Klinik2009;104(5):331-5. ">Weigand 2009</a>; <a href="./references#CD010981-bbs2-0145" title="ZahurUR , AlamM . Platelet transfusion practice in a tertiary care hospital. Medical Forum Monthly2002;13(7):27-9. ">Zahur 2002</a> </p> </li> </ul> </p> </section> </section> <section id="CD010981-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>None of the included studies were at low risk of bias in every domain, and all of the studies identified had some threats to validity. Only one study was deemed to be at low risk of bias in all domains other than blinding. </p> <p>See <a href="#CD010981-fig-0002">Figure 2</a> and <a href="#CD010981-fig-0003">Figure 3</a> for visual representations of the assessments of risk of bias across all studies and for each item in the individual studies. See the <a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a> section 'Risk of bias' table for further information about the bias identified within individual trials. </p> <div class="figure" id="CD010981-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010981-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010981-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010981-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>The four studies published in the 1970s and 1980s had significant threats to validity; the majority of these potential risks were due to a lack of detail provided on the specific criteria and were thus judged as at unclear risk of bias (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). </p> <section id="CD010981-sec-0067"> <h4 class="title">Allocation</h4> <p>Three studies reported on sequence generation and allocation concealment (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). We deemed two of these studies as at low risk of selection bias (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). In the third study, <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, we deemed the method of randomisation as at high risk of selection bias because the method of random sequence generation and allocation concealment performed (unpublished data reported by the author) meant study investigators could potentially predict the study group assignment. Randomisation was performed using 25 envelopes, each with four cards inside: 1) therapeutic/random donor, 2) therapeutic/single donor, 3) prophylactic/random donor, and 4) prophylactic/single donor. Participants' allocation was drawn from the envelope as they enrolled. Once all four cards in an envelope were used, a new envelope was opened. </p> <p>The three remaining studies did not report the method of allocation concealment or randomisation and have an unclear risk of selection bias (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). </p> </section> <section id="CD010981-sec-0068"> <h4 class="title">Blinding</h4> <p>All studies were at high or unclear risk of detection bias. Three studies reported that they were unblinded and were therefore judged as at high risk of detection bias (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Three studies did not report any mechanisms to blind outcome assessors, clinicians, or study participants to the intervention (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). It is likely these studies were unblinded, owing to the nature of the intervention and difficulty blinding clinicians and participants to transfusion intervention status. It is likely that clinicians and participants were aware of study group assignment and treatment. </p> <p>This may have been particularly problematic with respect to reporting outcomes with potentially high levels of subjectivity, such as enumerating significant bleeding events and participant reporting of bleeding events. Studies in which the bleeding assessor was also the person deciding whether a therapeutic platelet transfusion was appropriate were at the highest risk of this type of bias. </p> </section> <section id="CD010981-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Only one study, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, reported completeness of data and how missing data were dealt with, and we deemed this study as at low risk of attrition bias. In the rest of the studies there was insufficient reporting to allow assessment of whether data collection was complete, and we therefore deemed them as at unclear risk of attrition bias. </p> <p>The number of participants lost to follow‐up was quite low in all studies.</p> <p>Three studies reported using intention‐to‐treat analysis (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). In <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>, analysis was not by intention‐to‐treat, as two participants (randomised to the prophylactic arm) died from cerebral haemorrhages on day one of the study and were excluded from the analysis. </p> </section> <section id="CD010981-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Study protocols or clinical trials registration information were only available for two of the six studies (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> reported on all prespecified outcomes and was at low risk of reporting bias. <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> did not report a prespecified secondary outcome, "duration of thrombocytopenia below 10.000/µL", however they did report "duration of thrombocytopenia below 20.000/µL"; the implications of this are unclear. It was unclear whether any of the older studies were free of selective reporting, as study protocols were not available. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> reported on red cell and white cell transfusion in the abstract, however this was excluded from the final manuscript; whether these were prespecified outcomes within the study was unclear. </p> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported in the text that there was "no correlation of the incidence of bleeding with sex, pre‐transfusion haematocrit, concomitant corticosteroid therapy or the use of specific antineoplastic drugs", however none of these measures were reported further. </p> </section> <section id="CD010981-sec-0071"> <h4 class="title">Protocol deviation</h4> <p>Three of the six studies reported protocol deviation (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). There were low levels of protocol deviation in <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, and we therefore categorised this as at low risk of bias. Slight variation in protocol deviation between the treatment arms was noted in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, however the significance of this was unclear. </p> </section> <section id="CD010981-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>Only one study was at low risk of other biases (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). Although this was a multinational study and therefore at risk of variability in the assessment of bleeding, this was mitigated by a training and monitoring policy the study set up (see <a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). Multicentre studies are at risk of potential heterogeneity of reporting of outcomes at different sites. </p> <p>Three of the six studies were small (12 to 56 participants enrolled) (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). The small number of participants in these studies reduced the likelihood that participants were equivalent at baseline. Two studies did not have equivalent numbers of participants in each study arm at baseline (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>), and <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> did not report the number of participants in each study arm. We judged these three studies as at high risk of 'other bias'. </p> <p>Two studies reported interim data from the study prior to the study's completion (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). These interim results may have affected the behaviour of clinicians involved in these studies, including recruitment of participants, assessment and reporting of bleeding, and change in platelet prescription practice. </p> <section id="CD010981-sec-0073"> <h5 class="title">Risk of bias in the assessment and grading of bleeding</h5> <p>All methods of bleeding assessment are prone to performance and detection bias because it is a subjective measurement. </p> <p>Four of the six studies reported bleeding outcomes (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Bleeding was the primary outcome measure in one of these studies (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> <p>Three studies reported the method used to assess for the presence of bleeding (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (<a href="#CD010981-tbl-0003">Table 2</a>). </p> <div class="table" id="CD010981-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Method of bleeding assessment and grading</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bleeding primary outcome of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method of bleeding assessment reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinically significant bleeding definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bleeding severity scale used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RBC usage part of bleeding severity assessment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RBC transfusion policy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO Grade 2 or higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified WHO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the absence of bleeding a Hb &lt; 90 g/L</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO Grade 2 or higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified WHO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To maintain a Hb &gt; 80 g/L</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and severe bleeds.</p> <p>Mild bleeds not requiring active intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study specific</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study specific</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Hb: haemoglobin<br/>RBC: red blood cell </p> </div> </div> <p>In <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, participants were assessed daily for signs of bleeding and fundoscopic examination was performed twice daily once the platelet count was less than 20 x 10<sup>9</sup>/L. In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, an unblinded local research nurse performed daily bleeding assessments, or participants self reported bleeding in a bleeding diary. In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, experienced medical staff performed twice‐daily bleeding assessments. </p> <p>Three studies reported a bleeding severity scale (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). Both <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> used their own modifications of the WHO grading scale and defined clinically relevant bleeding as bleeding of WHO Grade 2 or higher. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> classified bleeds as mild or severe; mild bleeds were those that did not require active intervention. </p> <p>Two studies reported how an assessment of bleeding was converted into a bleeding grade (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, a validated computer algorithm performed grading of bleeding. In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, two investigators masked to treatment strategy transformed the bedside report into modified WHO categories. </p> <p>One of the main definitions for WHO Grade 3 bleeding, in the modified WHO criteria is bleeding necessitating red cell transfusion support. Four studies reported red cell transfusion requirements (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), however only two studies described their red cell transfusion policy (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). The red cell transfusion policy differed between studies, and this variance could potentially affect the assessment of bleeding grade and lead to bias. </p> </section> </section> </section> <section id="CD010981-sec-0074"> <h3 class="title" id="CD010981-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD010981-tbl-0001"><b>Summary of findings 1</b> Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</a> </p> <p>In all the included studies, we used the study's own definition of clinically significant bleeding, unless otherwise stated. If the study did not explicitly define clinically significant bleeding, we assumed that this was WHO Grade 2 or above bleeding. The two more recent studies used their own modifications of the WHO grading scale (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> defined mild bleeds as bleeds not needing active intervention, with no specific definition given for "severe" bleeds. </p> <section id="CD010981-sec-0075"> <h4 class="title">Primary outcome</h4> <p>Four of the six studies reported bleeding as an outcome measure (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). (See <a href="#CD010981-tbl-0004">Table 3</a>, <a href="#CD010981-tbl-0005">Table 4</a>, <a href="#CD010981-tbl-0006">Table 5</a> for individual study results.) The duration of follow‐up varied between studies. In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the median number of days on study was 30 days. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> followed up participants throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count less than 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <div class="table" id="CD010981-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Clinically significant bleeding event/participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted difference in proportions</p> <p>8.4%</p> <p>(90% CI 1.7, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a><b><sup> a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> <p>(301 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(36, 48) reported per treatment cycle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(343 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19%</p> <p>(14, 23)</p> <p>reported per treatment cycle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% vs 19%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup> b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> <p>(0.86, 1.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup> c</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.58</p> <p>(1.67, 12.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup>d</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.83</p> <p>(0.94, 3.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>RR: risk ratio </p> <p><sup>a</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, bleeding was reported per treatment cycle. Participants were followed until either the platelet count was self sustaining at 20 x 10<sup>9</sup>/L or higher for 2 days, a maximum of 30 days, at hospital discharge, when treatment failure occurred, at death or at study withdrawal, whichever occurred first. Only participants receiving autologous haematopoietic stem cell transplantation received one treatment cycle, and therefore the number of participants was equal to the number of treatment cycles. Participants receiving chemotherapy could have received up to seven cycles of treatment. </p> <p><sup>b</sup> Bleeding events in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count less than 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>c</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were not reported over this review's predefined outcome period of 30 days. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported bleeding outcome over the first 10 months of the study. </p> <p><sup>d</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were also reported from study enrolment until study closure. The mean number of months observed varied from 19.9 months in the prophylactic group to 20.4 months in the therapeutic group. </p> </div> </div> <div class="table" id="CD010981-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Total number of days on which significant bleeding event occurred per participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Days of clinically significant bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Days of clinically significant bleeding</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.7 +/‐ 2.9 (SD)</p> <p>days per participant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.2 +/‐ 2.0 (SD)</p> <p>days per participant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 1.52</p> <p>(1.14, 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup>b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation</p> <p><sup>a</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were not reported over this review's predefined outcome period of 30 days. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported bleeding outcome over the first 10 months of the study. </p> <p><sup>b</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were also reported from study enrolment until study closure. The mean number of months observed varied from 19.9 months in the prophylactic group to 20.4 months in the therapeutic group. </p> </div> </div> <div class="table" id="CD010981-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Number of participants with at least one episode of severe or life‐threatening bleeding</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants with severe bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 4</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3 + 4</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WHO Grade 3 and 4</p> <p>Odds ratio</p> <p>6.05</p> <p>(0.73, 279.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> <th align="left" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of</b> participants<b>with severe bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants with severe bleeding per treatment cycle</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 4</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a><b><sup> b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 (301 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.0159</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (343 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup> Bleeding events in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>b</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, bleeding was reported per treatment cycle. Participants were followed until either the platelet count was self sustaining at 20 x 10<sup>9</sup>/L or higher for 2 days, a maximum of 30 days, at hospital discharge, when treatment failure occurred, at death or at study withdrawal, whichever occurred first. Only participants receiving autologous haematopoietic stem cell transplantation received one treatment cycle, and therefore the number of participants was equal to the number of treatment cycles. Participants receiving chemotherapy could have received up to seven cycles of treatment. </p> </div> </div> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> followed participants until either the platelet count was self sustaining at 20 x 10<sup>9</sup>/L or higher for two days; a maximum of 30 days; at hospital discharge; when treatment failure occurred; at death or at study withdrawal, whichever occurred first. <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported bleeding events per treatment cycle. In the autologous HSCT group, the number of participants was equal to the number of treatment cycles, and therefore each participant received only one treatment cycle. Participants with AML had bleeding events reported per treatment cycles received, therefore the number of participants did not equal the number of treatment cycles. Consequently we were unable to include this data for the AML group in the meta‐analysis. </p> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> followed up participants from study enrolment until study closure. Bleeding outcomes and platelet transfusion requirements were reported for the first 10 months of the study and until study closure. The mean number of months observed varied from 20.4 months in the therapeutic‐only group to 19.9 months in the prophylactic group. </p> <section id="CD010981-sec-0076"> <h5 class="title">Number and severity of bleeding episodes within 30 days from the start of the study</h5> <p>Two of the six studies reported bleeding outcomes within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <section id="CD010981-sec-0077"> <h6 class="title">Number of participants with at least one bleeding episode</h6> <p>Two studies reported the number of participants with a clinically significant bleeding event (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (autologous HSCT participant data only)). We did not perform a meta‐analysis of the data from these two studies due to the significant statistical heterogeneity seen (I<sup>2</sup> = 88%) (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). We identified a probable cause for this heterogeneity, that is the different ways in which these two trials assessed and recorded bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). These results are represented graphically in <a href="./references#CD010981-fig-0004" title="">Analysis 1.1</a>. In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, there appeared to be an increased risk of bleeding events with a therapeutic‐only transfusion policy when compared with the prophylactic group; however, the 95% confidence interval (CI) crossed 1.0 (risk ratio (RR) 1.17, 95% CI 0.99 to 1.39). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, a therapeutic‐only transfusion policy was associated with increased risk of bleeding events per treatment cycle when compared with a prophylaxis policy (RR 3.45, 95% CI 1.66 to 7.17). </p> <p>Two studies did not report bleeding events over 30 days and therefore could not be included in the meta‐analysis, as they had varying definitions of study completion and reported clinically significant bleeding episodes over different time periods (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>). We sought additional data from study authors to enable us to perform meta‐analysis of bleeding outcomes, however individual bleeding data for the first 30 days postrandomisation were not available from <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, and the study author from <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> died prior to publication of this review. These studies both reported a similar effect with statistically increased clinically significant bleeding in the therapeutic‐only platelet transfusion group when compared with the prophylactic arm (see <a href="#CD010981-tbl-0004">Table 3</a>). </p> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported bleeding using different units of analysis, and we were therefore unable to be incorporate the data from the participants with AML in the meta‐analysis; further individual bleeding data per participant is pending. On review of the combined results in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (see <a href="#CD010981-tbl-0004">Table 3</a>), the study showed a statistically increased risk of bleeding events with a therapeutic‐only platelet transfusion policy when compared with a prophylactic platelet regimen. </p> </section> <section id="CD010981-sec-0078"> <h6 class="title">Total number of days on which bleeding occurred per participant</h6> <p>Two of the six studies reported the number of days with a significant bleeding event per participant (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) (see <a href="#CD010981-tbl-0005">Table 4</a>). However, only one of the studies, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, reported the total number of days within 30 days from the start of the study. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> did not report this outcome over 30 days and was therefore not included in the meta‐analysis. </p> <p>In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the number of days with clinically significant bleeding per participant was higher in the therapeutic‐only group than in the prophylactic group (mean difference (MD) 0.50, 95% CI 0.10 to 0.90) (<a href="./references#CD010981-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010981-sec-0079"> <h6 class="title">Number of participants with at least one episode of severe or life‐threatening bleeding</h6> <p>Three studies reported the number of participants with at least one episode of severe or life‐threatening bleeding (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (see <a href="#CD010981-tbl-0006">Table 5</a>). However, only two of the studies reported this within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). We were able to include the data from two studies in the meta‐analysis (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (autologous HSCT participant data only)). There was no evidence of a difference in the number of participants experiencing severe or life‐threatening bleeding between a therapeutic‐only or prophylactic platelet transfusion policy (RR 4.91, 95% CI 0.86 to 28.12), however the 95% CI was very wide. There was no evidence of statistical heterogeneity (<a href="./references#CD010981-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD010981-sec-0080"> <h6 class="title">Time to first bleeding episode from the start of the study</h6> <p>Three studies reported the time to the first significant bleeding event (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported graphically the time to onset of first bleeding episode. We extracted the data from the graph in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> using the methodology outlined by <a href="./references#CD010981-bbs2-0208" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8(16). [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> also reported graphically the percentage of participants free of bleeding at intervals following randomisation over the entire trial period. We were unable to extract data from the graph in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> as it was not possible to derive the timing of the first data point. </p> <p>We did not perform a meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> because of the significant statistical heterogeneity seen (I<sup>2</sup> = 90%). The individual study results have been presented graphically (<a href="./references#CD010981-fig-0007" title="">Analysis 1.4</a>). We identified a probable cause for this heterogeneity, that is the different ways in which these two trials assessed and recorded bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (hazard ratio (HR) 1.30, 95% CI 1.03 to 1.64). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (HR 2.61, 95% CI 1.84 to 3.72). </p> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported from their analysis that the time to onset of clinically significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (study authors reported a P value of 0.014). </p> </section> </section> </section> <section id="CD010981-sec-0081"> <h4 class="title">Secondary outcomes</h4> <section id="CD010981-sec-0082"> <h5 class="title">Mortality within 30 and 90 days from the start of the study</h5> <p>Four of the six studies reported all‐cause mortality as an outcome (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>All six studies reported mortality due to bleeding as an outcome (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). The duration of follow‐up varied widely between studies, and the definition of study completion also varied between studies, hence we could not perform pooling of these studies (see <a href="#CD010981-tbl-0007">Table 6</a>). </p> <div class="table" id="CD010981-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Mortality</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality as per study definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study follow‐up definitions</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality within 30 days</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality within 90 days</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to infection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause/ due to bleeding/ due to infection</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study follow‐up was when plt count was self sustaining at more than 20 x 10<sup>9</sup>/L for 2 days, or a maximum of 30 days, or at hospital discharge, or treatment failure, death or at study withdrawal, whichever occurred first. </p> <p>Participants receiving chemotherapy could have received up to 7 cycles of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Mortality reported within 1 month/course of chemotherapy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality reported within 1 month/course of chemotherapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L). This often included more than 1 period of thrombocytopenia per participant. </p> <p>Bacterial or fungal sepsis (or both) was a contributing factor in 8 of the deaths.</p> <p>11 of the 14 haemorrhagic deaths were in participants who had plt alloantibodies</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 20.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 19.9 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study follow‐up not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>plt: platelet</p> </div> </div> <section id="CD010981-sec-0083"> <h6 class="title">All‐cause mortality</h6> <p>Two of the six studies reported all‐cause mortality within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> <p>Only one of these two studies reported any deaths in either study arm (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) (<a href="./references#CD010981-fig-0008" title="">Analysis 1.5</a>), and this study showed no evidence of a difference in mortality between the therapeutic‐only and prophylactic platelet transfusion groups (RR 1.24, 95% CI 0.34 to 4.58). </p> <p>None of the studies reported all‐cause mortality within 90 days from the start of the study. </p> </section> <section id="CD010981-sec-0084"> <h6 class="title">Mortality secondary to bleeding</h6> <p>Four of the six studies reported mortality secondary to bleeding within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (autologous HSCT participants only)). None of these studies reported any secondary deaths due to bleeding (see <a href="#CD010981-tbl-0007">Table 6</a>). </p> <p>Two of the six studies reported mortality secondary to bleeding within 90 days from the start of the study (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (autologous HSCT participants only)) (see <a href="#CD010981-tbl-0007">Table 6</a>). We were unable to peform a meta‐analysis because only one of the studies reported any deaths due to bleeding (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>) (<a href="./references#CD010981-fig-0009" title="">Analysis 1.6</a>). This study showed no statistical difference in mortality due to bleeding between a therapeutic‐only platelet transfusion policy and prophylactic platelet transfusions (RR 2.40, 95% CI 0.81 to 7.15). </p> </section> <section id="CD010981-sec-0085"> <h6 class="title">Mortality secondary to infection</h6> <p>Only one of the six studies reported mortality secondary to infection within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) (see <a href="#CD010981-tbl-0007">Table 6</a>). There were 4/301 deaths in the therapeutic‐only platelet transfusion group compared with 3/299 deaths in the prophylactic platelet transfusion group. All deaths secondary to infection were categorised as being unlikely to be related to the study intervention. </p> <p>None of the studies reported mortality due to infection within 90 days from the start of the study. </p> </section> </section> <section id="CD010981-sec-0086"> <h5 class="title">Number of platelet transfusions per participant and number of platelet components per participant within 30 days from the start of the study </h5> <p>Four out of the six studies reported the number of platelet transfusions given per participant (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (see <a href="#CD010981-tbl-0008">Table 7</a>). However, only two of these four studies reported the number of platelet transfusions given within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <div class="table" id="CD010981-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Number of platelet transfusions or units</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet dose/transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet transfusions/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet units transfused/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 adult unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 +/‐ 2.6 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.62</p> <p>(0.51, 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 +/‐ 3.3 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.67</p> <p>(0.55, 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 +/‐ 3.2 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 +/‐ 3.6 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.30</p> <p>(‐1.85, ‐0.75)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 platelet unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.63</p> <p>(1.4, 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33.5% reduction in platelet transfusion</p> <p>(22.2, 43.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.44</p> <p>(2.2, 2.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐donor unit comprised a mean of 6.8 platelet concentrates, with an average yield of 0.8 x 10<sup>11</sup> plts/unit. </p> <p>Single‐donor unit had a mean of 4.8 x 10<sup>11</sup> plts/collection </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a><b><sup>c</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 units/m<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8/participant<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1/participant<sup>d</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Number in each arm not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 x 10<sup>11</sup> plts/transfusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet dose/transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet transfusions/course of chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet units transfused/course of chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.1 +/‐ 3.4 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐15.8 (‐19.2, ‐12.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.9 +/‐ 5.9 (SD)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MD: mean difference<br/>SD: standard deviation </p> <p><sup>a</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, the analysis was adjusted for the stratification variables age (&lt; 50 years and ≥ 50 years) and sex, and a random effect for repeated measures data of a participant’s treatment cycles clustered in centres. </p> <p><sup>b</sup> Platelet transfusions in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>c</sup> Platelet transfusions in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were reported over a 10‐month period. </p> <p><sup>d</sup> Not specified whether this value is a mean or a median (no further information available ‐ author has died) </p> </div> </div> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>'s primary outcome was number of platelet transfusions given during a standardised observation time of 14 days per participant. The observation time was standardised to fairly compare the number of platelet transfusions between the two transfusions groups despite a different duration of observation in participants who underwent differing numbers of treatment cycles. We therefore included this data in the meta‐analysis. Both of these studies reported a clear reduction in the number of platelet transfusions per participant. The meta‐analysis showed a standardised mean reduction of 0.50 platelet transfusions per participant (95% CI ‐0.63 to ‐0.37) (<a href="./references#CD010981-fig-0010" title="">Analysis 1.7</a>). </p> <p>Three out of the six studies reported the number of platelet components given per participant (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) (see <a href="#CD010981-tbl-0008">Table 7</a>). </p> <p>Only one study reported the number of platelet components per participant within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). There was a mean reduction of 1.30 platelet units per participant (95% CI ‐1.85 to ‐0.75) (see <a href="#CD010981-tbl-0008">Table 7</a>). </p> </section> <section id="CD010981-sec-0087"> <h5 class="title">Number of red cell transfusions per participant and number of red cell components per participant within 30 days from the start of the study </h5> <p>Four out of the six studies reported red cell transfusion requirements as an outcome (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (see <a href="#CD010981-tbl-0009">Table 8</a>). Two of the six studies reported the number of red cell transfusions per participant within 30 days of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (autologous HSCT participants only)). The meta‐analysis showed there was no evidence of a difference in red cell transfusions per participant (MD 0.11, 95% CI ‐0.14 to 0.36) (<a href="./references#CD010981-fig-0011" title="">Analysis 1.8</a>). There was a moderate degree of heterogeneity seen between studies (I<sup>2</sup> = 65%), and this may reflect differences in red cell transfusion policies. </p> <div class="table" id="CD010981-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Number of red cell transfusions per participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell transfusions/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell units/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.5 +/‐ 1.8 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio</p> <p>1.14</p> <p>(0.96, 1.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 3.0 +/‐ 3.4 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate Ratio</p> <p>1.24</p> <p>(1.04, 1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.5 +/‐ 1.7 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 2.8 +/‐ 3.1 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.20</p> <p>(‐0.32, 0.72)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 3.14</p> <p>(2.81, 3.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 2.85</p> <p>(2.58, 3.12)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>Number in each arm not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell transfusions/course of treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell units/course of treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 +/‐ 1.0 (SE)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐0.6</p> <p>(‐1.34, 0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 +/‐ 1.0 (SE)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MD: mean difference<br/>SD: standard deviation<br/>SE: standard error </p> <p><sup>a</sup> Red cell transfusions in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> </div> </div> <p>Two out of the six studies reported number of red cell components per participant as an outcome (<a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) (see <a href="#CD010981-tbl-0009">Table 8</a>). </p> <p>Only one study, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, reported the mean number of red cell components per participant within 30 days from the start of the study (MD 0.20, 95% CI ‐0.32 to 0.72) (see <a href="#CD010981-tbl-0009">Table 8</a>). </p> </section> <section id="CD010981-sec-0088"> <h5 class="title">Platelet transfusion interval within 30 days from the start of the study</h5> <p>None of the six studies reported the platelet transfusion interval.</p> </section> <section id="CD010981-sec-0089"> <h5 class="title">Proportion of participants requiring additional interventions to stop bleeding within 30 days from the start of the study </h5> <p>Two studies provided unpublished data on the use of blood product and surgical interventions to stop WHO Grade 3 and 4 bleeding (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p><b>Additional surgical interventions to stop bleeding</b> </p> <p>Both <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> (unpublished data) reported the use of surgical, endoscopic, or other procedures to stop bleeding. There was no evidence of a difference in the use of surgical or other procedures (RR 3.96, 95% CI 0.44 to 35.27) (<a href="./references#CD010981-fig-0012" title="">Analysis 1.9</a>). </p> <section id="CD010981-sec-0090"> <h6 class="title">Additional medical interventions to stop bleeding</h6> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (unpublished data) reported the use of medical interventions to stop bleeding. There was no evidence of a difference in the use of medical interventions to stop bleeding between the therapeutic‐only platelet transfusion arm and the prophylactic arm (RR 4.97, 95% CI 0.24 to 103.02) (<a href="./references#CD010981-fig-0013" title="">Analysis 1.10</a>). The number of events was low, and the 95% CI was very wide. Interventions <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> reported included tranexamic acid and vitamin K. </p> </section> <section id="CD010981-sec-0091"> <h6 class="title">Additional blood product interventions to stop bleeding</h6> <p>Two of the six studies reported the use of blood product interventions to stop WHO Grade 3 and 4 bleeding (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (unpublished data), and no studies reported the use of blood products to stop WHO Grade 2 bleeding. There was no evidence of a difference in the use of blood products to stop WHO Grade 3 or 4 bleeding between the therapeutic‐only platelet transfusion arm and the prophylactic arm (RR 0.71, 95% CI 0.14 to 3.55) (<a href="./references#CD010981-fig-0014" title="">Analysis 1.11</a>). </p> <p>Blood products used to stop bleeding included fresh frozen plasma, clotting factor concentrate, and factor XIII. There were no reports of the use of cryoprecipitate, fibrinogen, or recombinant factor VIIa to stop bleeding. </p> </section> </section> <section id="CD010981-sec-0092"> <h5 class="title">Overall survival within 30, 90, and 180 days from the start of the study</h5> <p>Three of the six studies reported overall survival (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). However, only one study reported overall survival rate at 30 days: 297/301 in the therapeutic‐only group and 297/299 in the prophylactic group (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> <p>None of the studies reported overall survival within 90 or 180 days from the start of the study. </p> </section> <section id="CD010981-sec-0093"> <h5 class="title">Proportion of participants achieving complete remission within 30 and 90 days from the start of the study </h5> <p>Only one of the six studies reported complete or partial remission rates (<a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). The study reported complete remission rates after one course of chemotherapy. Those who did not achieve complete remission were generally given a second course of chemotherapy. Complete remission was achieved in 9/17 from the prophylactic platelet transfusion group and 6/12 in the specific interventions group (therapeutic‐only platelet transfusions and platelet transfusions when there was a 50% or more decline in platelet count in the preceding 24hours) (RR 0.94, 95% CI 0.46 to 1.94) (<a href="./references#CD010981-fig-0015" title="">Analysis 1.12</a>). </p> <p>None of the studies reported complete remission rates at 30 or 90 days.</p> </section> <section id="CD010981-sec-0094"> <h5 class="title">Total time in hospital within 30 days from the start of the study</h5> <p>Two of the six studies reported the total time of hospitalisation (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). However, the studies reported this data in different formats, and therefore we could not combine them in a meta‐analysis. <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> reported a median duration of inpatient stay per participant of 12 days (interquartile range (IQR) 9 to 18) in the therapeutic‐only group and 12 days (IQR 9 to 18) in the prophylactic group. <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported mean number of days in hospital: 18 days (95% CI 17 to 18) in the therapeutic‐only group, compared with 17 days (95% CI 16 to 19) in the prophylactic group; the study's reported P value was 0.69. There was no evidence of a difference in the total time in hospital between the two intervention groups in these two studies. </p> </section> <section id="CD010981-sec-0095"> <h5 class="title">Adverse effects of treatments within 30 and 90 days from the start of the study</h5> <p>Five of the six studies reported adverse effects of transfusion (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <section id="CD010981-sec-0096"> <h6 class="title">Transfusion reactions</h6> <p>Two of the five studies reported the occurrence of transfusion reactions within 30 days from the start of the study (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). We performed a meta‐analysis of data from these two studies and observed no evidence of a difference in the number of transfusion reactions between a therapeutic‐only or prophylactic platelet transfusion policy (RR 1.02, 95% CI 0.62 to 1.68). There was no evidence of heterogeneity (<a href="./references#CD010981-fig-0016" title="">Analysis 1.13</a>). There was considerable difference in the rates of reported transfusion reactions between these studies. This may be a reflection of variability between the studies in how transfusion reactions were defined, identified, and reported. </p> </section> <section id="CD010981-sec-0097"> <h6 class="title">Thromboembolic disease</h6> <p>None of the studies reported the occurrence of thromboembolic disease.</p> </section> <section id="CD010981-sec-0098"> <h6 class="title">Transfusion‐transmitted infection</h6> <p>None of the studies reported the occurrence of transfusion‐transmitted infection.</p> </section> <section id="CD010981-sec-0099"> <h6 class="title">Human leukocyte antigen antibodies/platelet refractoriness</h6> <p>Three of the five studies reported platelet refractoriness as an outcome (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>) (see <a href="#CD010981-tbl-0010">Table 9</a>). Two of the studies defined platelet refractoriness (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>). <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> defined it as bleeding for more than four days, in which thrombocytopenia persists in the face of repeated platelet transfusions. <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> defined platelet refractoriness as a corrected count increment of less than 10 x 10<sup>9</sup>/L following two or more consecutive transfusions in the absence of fever, disseminated intravascular coagulopathy, splenomegaly, or sepsis. </p> <div class="table" id="CD010981-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Platelet refractoriness</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet refractoriness</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of platelet refractoriness</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of study</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corrected count increment of &lt; 10 x 10<sup>9</sup>/L following 2 or more consecutive transfusions in the absence of fever, disseminated intravascular coagulopathy, splenomegaly, or sepsis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L). This often included more than 1 period of thrombocytopenia per participant </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding for more than 4 days in which thrombocytopenia persists in the face of repeated platelet transfusions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 20.4 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 19.9 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> </tbody> </table> </div> <p>No studies reported platelet refractoriness within 30 days of the start of the study (see <a href="#CD010981-tbl-0010">Table 9</a>). </p> </section> </section> <section id="CD010981-sec-0100"> <h5 class="title">Quality of life, as defined by the individual studies</h5> <p>None of the six studies reported any quality‐of‐life outcomes.</p> </section> <section id="CD010981-sec-0101"> <h5 class="title">Prespecified subgroup analyses</h5> <p>See <a href="#CD010981-tbl-0011">Table 10</a>. </p> <div class="table" id="CD010981-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Subgroup analyses for disease and treatment category</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="2" rowspan="1" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Acute leukaemia</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymphoma or myeloma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CML or other cancer</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Autologous stem cell transplant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Allogeneic stem cell transplant</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants with at least 1 clinically significant bleeding episode<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.64</p> <p>(1.11, 2.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07</p> <p>(0.88, 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07</p> <p>(0.50, 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.55</p> <p>(1.05, 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50</p> <p>(0.86, 2.61)</p> </td> </tr> <tr> <td align="left" class="headercell" colspan="2" rowspan="1" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Acute leukaemia</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymphoma or myeloma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CML or other cancer</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Autologous stem cell transplant</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Chemotherapy/</b> </p> <p><b>Allogeneic stem cell transplant</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Total number of days on which bleeding occurred per participant<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>599</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 1.52</p> <p>(1.14, 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.30</p> <p>(‐0.07, 0.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MD 1.20</p> <p>(0.22, 2.18)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants with at least 1 episode of severe or life‐threatening bleeding<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.91 <br/>(0.86, 28.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.89</p> <p>(0.58, 41.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>RR 2.97</p> <p>(0.31, 27.98)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Time to first bleeding episode<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.70</p> <p>(‐3.16, 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MD ‐6.00</p> <p>(‐9.52, ‐2.48)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>CML: chronic myelogenous leukemia<br/>MD: mean difference<br/>RR: risk ratio </p> <p><sup>1</sup> Follow‐up: median 30 days. Length of follow‐up in the primary study contributing to this outcome was 30 days. Bleeding assessed using modified WHO grading scale. </p> <p><sup>2</sup> A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, a therapeutic‐only transfusion policy was associated with increased risk of bleeding events per treatment cycle when compared with a prophylaxis policy (RR 3.45, 95% CI 1.66 to 7.17). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the 95% CI crossed 1.0 (RR 1.17, 95% CI 0.99 to 1.39). </p> <p><sup>3</sup>A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, there was no statistically significant difference in the number of clinically significant bleeding episodes between a therapeutic‐only or prophylactic platelet transfusion policy (RR 1.04, 95% CI 0.85 to 1.28). However, in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> there was a statistically significant difference (RR 3.45, 95% CI 1.66 to 7.17). </p> <p><sup>4</sup>A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (hazard ratio 1.30, 95% CI 1.03 to 1.64). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (hazard ratio 2.61, 95% CI 1.84 to 3.72). </p> </div> </div> <section id="CD010981-sec-0102"> <h6 class="title">Presence of fever</h6> <p>None of the studies commented on an association between fever and bleeding risk.</p> </section> <section id="CD010981-sec-0103"> <h6 class="title">Underlying disease</h6> <p>Three studies reported bleeding outcome data on the basis of the participants' underlying haematological disease (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>) (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> also provided unpublished data) (<a href="./references#CD010981-fig-0017" title="">Analysis 1.14</a>). </p> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported separate subgroup data for participants with AML and autologous HSCT. The data for the participants being treated for AML and autologous HSCT were reported per treatment cycle rather than per participant, and hence participants with AML may have received more than one treatment cycle, with the consequence that we were unable to include the data in the meta‐analysis. </p> <p>The AML subgroup from <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> had increased bleeding rates in the therapeutic‐only platelet transfusion group. There were 98 bleeding episodes per 198 treatment cycles with a therapeutic‐only regimen compared with 57 bleeding episodes per 245 treatment cycles in participants receiving a prophylactic platelet transfusion (study authors reported a P value of less than 0.0001). </p> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> did not report the outcome within 30 days. </p> <section id="CD010981-sec-0104"> <p><b>Number of participants with at least one clinically significant bleeding episode</b></p> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> reported bleeding outcome data on the basis of the participants' underlying haematological disease for three subgroups: acute leukaemia, lymphoma/myeloma, and chronic myelogenous leukaemia (CML)/other cancer within 30 days from the start of the study. </p> <p>Analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> for participants with acute leukaemia showed there was an increase in the number of participants developing clinically significant bleeding with a therapeutic‐only transfusion policy when compared with a prophylactic policy (RR 1.64, 95% CI 1.11 to 2.44) (<a href="./references#CD010981-fig-0017" title="">Analysis 1.14</a>). </p> <p>Subgroup analysis from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> for participants with lymphoma/myeloma showed no evidence of a difference in bleeding events between the intervention groups (RR 1.07, 95% CI 0.88 to 1.31). Similarly, there was no evidence of a difference in bleeding rates for participants with CML or other cancer (RR 1.07, 95% CI 0.50 to 2.28) (<a href="./references#CD010981-fig-0017" title="">Analysis 1.14</a>). </p> </section> </section> <section id="CD010981-sec-0105"> <h6 class="title">Type of treatment</h6> <p>Two trials reported bleeding outcome data separately for participants receiving autologous HSCT (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (unpublished data) also reported bleeding outcomes for participants receiving chemotherapy/allogeneic HSCT. </p> <section id="CD010981-sec-0106"> <p><b>Number of participants with at least one clinically significant bleeding episode</b></p> <p>We did not perform a meta‐analysis of the data for participants receiving autologous HSCT as there was considerable statistical heterogeneity between these two studies: I<sup>2</sup> = 90% (<a href="./references#CD010981-fig-0018" title="">Analysis 1.15</a>). This statistical heterogeneity may have arisen because of the known differences in how bleeding was assessed and graded, the difference in autologous stem cell protocols and source of stem cells used for the transplantation. There was variability in the baseline participant characteristics between the two studies, specifically with regard to underlying haematological disease requiring HSCT. In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, no participants received autologous HSCT for acute leukaemia, whilst in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, 14 participants were transplanted for acute leukaemia. </p> <p>In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, there was no evidence of a difference in the number of clinically significant bleeding episodes between a therapeutic‐only or prophylactic platelet transfusion policy (RR 1.04, 95% CI 0.85 to 1.28). However, in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> there was a difference (RR 3.45, 95% CI 1.66 to 7.17) (<a href="./references#CD010981-fig-0018" title="">Analysis 1.15</a>). </p> <p>In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>(unpublished data), there was a difference in the number of clinically significant bleeding episodes between a therapeutic‐only and prophylactic platelet transfusion policy in the chemotherapy group (RR 1.55, 95% CI 1.05 to 2.28) (<a href="./references#CD010981-fig-0018" title="">Analysis 1.15</a>). There was no evidence of a difference in bleeding between intervention groups in the allogeneic HSCT group in <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (RR 1.50, 95% CI 0.86 to 2.61) (<a href="./references#CD010981-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD010981-sec-0107"> <p><b>Total number of days in which bleeding occurred per participant</b></p> <p>The number of days with a significant bleeding event per participant was reported in <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> for the autologous HSCT and chemotherapy/allogeneic HSCT groups <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (unpublished data). In the autologous HSCT group, there was no difference in the number of days with clinically significant bleeding per participant between the therapeutic‐only platelet transfusion group and the prophylactic group (MD 0.30, 95% CI ‐0.07 to 0.67) (<a href="./references#CD010981-fig-0019" title="">Analysis 1.16</a>). </p> <p>In the chemotherapy/allogeneic HSCT group (unpublished data), the number of days with clinically significant bleeding per participant was higher in the therapeutic‐only group than in the prophylactic platelet transfusion group (MD 1.20, 95% CI 0.22 to 2.18) (<a href="./references#CD010981-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD010981-sec-0108"> <p><b>Number of participants with at least one episode of severe or life‐threatening bleeding</b></p> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> reported the number of participants with at least one episode of severe or life‐threatening bleeding for participants receiving autologous HSCT. <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (unpublished data) also reported severe or life‐threatening bleeding in the chemotherapy/allogeneic HSCT group. </p> <p>In the autologous HSCT group, there was no evidence of a difference in the number of participants experiencing severe or life‐threatening bleeding between a therapeutic‐only or prophylactic platelet transfusion policy (RR 4.89, 95% CI 0.58 to 41.41) (<a href="./references#CD010981-fig-0020" title="">Analysis 1.17</a>); however, the 95% CI was very wide. </p> <p>In the chemotherapy/allogeneic HSCT group from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> (unpublished data), there was no evidence of a difference in the number of participants experiencing severe or life‐threatening bleeding between a therapeutic‐only or prophylactic platelet transfusion policy (RR 2.97, 95% CI 0.31 to 27.98) (<a href="./references#CD010981-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD010981-sec-0109"> <p><b>Time to first bleeding episode from the start of the study</b></p> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> reported the time to first bleeding episode from the start of the study for the autologous HSCT and chemotherapy/allogeneic HSCT groups (unpublished data). In the autologous HSCT group, there was no evidence of a difference in the time to onset of significant bleeding between the therapeutic‐only group and prophylaxis group (MD ‐0.70, 95% CI ‐3.16 to 1.76) (<a href="./references#CD010981-fig-0022" title="">Analysis 1.19</a>). </p> <p>In the chemotherapy/allogeneic HSCT group (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> unpublished data), the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (MD ‐6.00, 95% CI ‐9.52 to ‐2.48) (<a href="./references#CD010981-fig-0022" title="">Analysis 1.19</a>). </p> </section> </section> <section id="CD010981-sec-0110"> <h6 class="title">Age of participant</h6> <p>One study, <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, provided unpublished data looking at the number of participants with at least one bleeding episode in participants aged 18 to less than 60 years and participants aged 60 years or older. In participants aged 18 to less than 60 years, there was no evidence of a difference in bleeding rates between the treatment groups (RR 1.15, 95% CI 0.90 to 1.47). Similarly, in participants aged 60 years or older, there was no evidence of a difference in bleeding rates seen (RR 1.19, 95% CI 0.93 to 1.51) (<a href="./references#CD010981-fig-0023" title="">Analysis 1.20</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010981-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010981-sec-0111"></div> <section id="CD010981-sec-0112"> <h3 class="title" id="CD010981-sec-0112">Summary of main results</h3> <p>This Cochrane systematic review intended to evaluate whether a therapeutic‐only platelet transfusion policy (platelet transfusions given when a patient bleeds) is as effective and safe as a prophylactic platelet transfusion policy (platelet transfusions given to prevent bleeding, usually when the platelet count falls below a given threshold) in people with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation. </p> <p>We identified seven RCTs that met our inclusion criteria, one of which is currently recruiting participants (<a href="./references#CD010981-bbs2-0149" title="NCT01615146. Outpatient platelet transfusions in myelodysplastic syndromes and leukemia: The OPTIMAL pilot. http://ClinicalTrials.gov/show/NCT01615146. Accessed 16 April 2013. ">NCT01615146</a>). We included six trials that compared the effect of a therapeutic‐only versus prophylactic platelet transfusion policy in the review. These trials were carried out over a 35‐year period and enrolled 1195 participants from fairly comparable patient populations. Five of these studies contained separate data for each arm and could therefore be critically appraised. </p> <section id="CD010981-sec-0113"> <h4 class="title">Clinically significant bleeding events</h4> <p>One of the main challenges within this review was the variability between studies in the assessment and grading of bleeding, the time period for which bleeding was reported across, and the units of analysis. The two recent studies used their own modifications of the WHO classification scale (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). WHO Grade 3 bleeding was defined as bleeding requiring red cell transfusions, however the red cell transfusion polices varied between studies. The method in which bleeding was recorded varied between studies and hampered the incorporation of study data into the meta‐analysis. <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> recorded bleeding in participants with AML per treatment cycle, and we were therefore unable to include it in the meta‐analysis. The time period for which bleeding was reported across was not consistent between trials. </p> <p>For the primary outcome (number of participants with at least one bleeding episode within 30 days from the start of the study), we observed significant statistical heterogeneity between studies, and were therefore unable to perform a meta‐analysis. This statistical heterogeneity may relate to the different methods the studies used to assess and grade bleeding and the different participant populations, in particular underlying disease and treatment categories. </p> <p>Whilst we were unable to perform a meta‐analysis for clinically significant bleeding events, all studies individually showed a similar effect. When compared with a prophylactic platelet transfusion policy, a therapeutic‐only platelet transfusion policy was associated with increased rates of clinically significant bleeding events. </p> <p>One study reported the number of days with a clinically significant bleeding event per participant, and this was statistically higher in the therapeutic‐only group than in the prophylactic group. </p> <p>There was insufficient evidence to determine whether there was any difference in the number of participants with severe or life‐threatening bleeding between a therapeutic‐only transfusion policy and a prophylactic policy. The numbers of episodes of severe and life‐threatening bleeding were small, and whilst we saw no statistical difference between treatment interventions, the confidence intervals were wide. Larger studies would be needed to detect any difference in life‐threatening bleeding rates. </p> <p>The time to first bleeding event appeared shorter in participants receiving a therapeutic‐only platelet transfusion policy versus a prophylactic platelet transfusion policy. </p> <p>Rates of bleeding appeared to differ amongst different participant disease‐type and treatment groups. </p> <p>We were unable to perform a meta‐analysis for bleeding rates in participants with acute leukaemia. However, two studies individually reported a statistically increased rate of bleeding in participants with acute leukaemia being managed with a therapeutic‐only platelet transfusion policy versus a prophylactic policy. </p> <p>One study reported rates of bleeding for participants with lymphoma/myeloma and CML/other haematological malignancies and found similar rates of bleeding in both therapeutic‐only and prophylactic transfusion arms (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). Further evidence is needed to confirm or refute these findings. </p> <p>There was inconclusive evidence in participants receiving autologous HSCT as to whether a therapeutic‐only platelet transfusion policy was associated with increased rates of clinically significant bleeding. There was significant heterogeneity between studies, and one study had wide 95% CIs. This statistical heterogeneity may have arisen because of the known differences in the way that bleeding was assessed, but may also be due to the different indications for HSCT, differences in the conditioning regimens, stem cell protocols, and the source of stem cells used for transplantation. </p> <p>Adopting a therapeutic‐only platelet transfusion policy would significantly reduce the number of platelet transfusions needed, however we did not assess the cost‐effectiveness of introducing such a policy. </p> <section id="CD010981-sec-0114"> <h5 class="title">Mortality</h5> <p>There was insufficient evidence to determine any difference in all‐cause mortality within 30 days of the start of the study between participants receiving a therapeutic‐only versus a prophylactic platelet transfusion policy. The results of the individual studies suggested that there was no difference in all‐cause mortality between the two intervention groups. However, due to the low mortality rates within the included studies, larger studies would be required to detect a statistical difference. There was insufficient evidence to determine whether there was any effect of a therapeutic‐only platelet transfusion policy on mortality rates due to bleeding. </p> <p>There was insufficient evidence to determine if there was any difference in overall survival rates at 30 days between treatment arms. </p> </section> <section id="CD010981-sec-0115"> <h5 class="title">Adverse events</h5> <p>There was no evidence of any difference in the frequency of adverse events such as transfusion reactions between a therapeutic‐only platelet transfusion policy and prophylactic platelet transfusion policy. These findings should be taken in the context that there was a large difference in the rates of reported transfusion reactions between the included studies suggesting that there was variability between how studies defined, identified, and reported transfusion reactions. </p> </section> <section id="CD010981-sec-0116"> <h5 class="title">Transfusions</h5> <p>There was a clear reduction in the number of participants receiving platelet transfusions in the therapeutic‐only platelet transfusion arm when compared with the prophylactic platelet transfusion arm. </p> <p>There was no evidence of a difference in red cell transfusions between treatment groups.</p> </section> <section id="CD010981-sec-0117"> <h5 class="title">Quality of life</h5> <p>None of the studies reported quality of life.</p> <p>Overall, a therapeutic‐only platelet transfusion policy did not appear as safe and effective as a prophylactic platelet transfusion policy with regard to rates of clinically significant bleeding. </p> <p>In summary, the findings of the review led to the following main conclusions:</p> <p> <ul id="CD010981-list-0013"> <li> <p>An increased proportion of participants bled with a therapeutic‐only platelet transfusion policy. </p> </li> <li> <p>The number of days with clinically significant bleeding increased with a therapeutic‐only platelet transfusion policy. </p> </li> <li> <p>There was insufficient evidence to determine any difference in severe or life‐threatening bleeding. </p> </li> <li> <p>Time to first bleeding episode was shorter in the therapeutic‐only platelet transfusion group than in the prophylactic platelet transfusion group. </p> </li> <li> <p>There was insufficient evidence to determine any difference in all‐cause mortality.</p> </li> <li> <p>There was a clear reduction in the number of platelet transfusions per participant in the therapeutic‐only arm. </p> </li> <li> <p>No study reported quality of life.</p> </li> </ul> </p> </section> </section> </section> <section id="CD010981-sec-0118"> <h3 class="title" id="CD010981-sec-0118">Overall completeness and applicability of evidence</h3> <p>This review provides the most up‐to‐date assessment of the effectiveness and safety of a therapeutic‐only platelet transfusion policy compared with administering prophylactic platelet transfusions when the platelet count goes below a certain threshold. This review identified two recently completed RCTs and a trial from the 1980s that had not been reviewed previously.  </p> <p>There is evidence that haematology patients receiving myelosuppressive chemotherapy or HSCT had increased clinically significant bleeding events with a therapeutic‐only platelet transfusion policy when compared with a prophylactic platelet transfusion policy. A prophylactic platelet transfusion policy appeared safer and should be continued as standard of care. </p> <p>The results of this meta‐analysis should not be interpreted without considering the impact of the following factors: </p> <p> <ul id="CD010981-list-0014"> <li> <p>The studies included in this review range over a 35‐year period (1978 to 2013), during which chemotherapy protocols, predicted overall survival rates, and supportive care, including transfusion, have changed substantially. </p> </li> <li> <p>The recording of bleeding is subjective, and between centres there is variability in the assessment, grading, investigation, and recording of bleeding. The same bleeding scale may even be interpreted and applied differently, particularly with respect to red cell transfusion. </p> </li> <li> <p>A number of studies showed a similar effect, that is increased clinically significant bleeding in the therapeutic‐only platelet transfusion group when compared with the prophylactic platelet transfusion group (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). We could not integrate the results from the individual studies into a meta‐analysis because the studies reported bleeding outcomes over different time periods, had varying definitions of study completion, or used different units of analysis. </p> </li> <li> <p>We could not analyse all endpoints from all the studies for this review due to varying methods of reporting bleeding. One of the larger studies conducted, <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, reported bleeding outcomes for the AML subgroup per treatment cycle, and could not be included in the meta‐analysis for bleeding events. </p> </li> <li> <p>Our prespecified time frames for outcome measurement resulted in the exclusion of a number of studies from meta‐analysis. We could not include <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, a medium‐sized study, for bleeding rates and mortality data due to differences in follow‐up period. </p> </li> <li> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> was only published in abstract form, as the full‐text article was not accepted for publication. </p> </li> <li> <p>We were unable to obtain all data from study authors to be used quantitatively in the meta‐analysis. </p> </li> <li> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a> did not have any usable data; the number of participants in each treatment arm was not stated, and it was therefore excluded from any quantitative analysis. </p> </li> <li> <p>The number of participants lost to follow‐up was quite low in all studies, and there were therefore minimal implications of missing outcome data. </p> </li> <li> <p>Different studies used different formats for expressing results such as overall survival, and consequently could not be analysed together. </p> </li> <li> <p>Within the same patient subpopulation there may be significant differences between the type of chemotherapy and number of courses administered (induction chemotherapy versus consolidation therapy). </p> </li> <li> <p>We saw differences in the baseline characteristics of participants receiving HSCT, in particular indication for stem cell transplantation. </p> </li> </ul> </p> </section> <section id="CD010981-sec-0119"> <h3 class="title" id="CD010981-sec-0119">Quality of the evidence</h3> <p>All studies were RCTs, however they were all prone to bias and had threats to validity. See <a href="#CD010981-fig-0002">Figure 2</a> and <a href="#CD010981-fig-0003">Figure 3</a> for visual representations of the assessments of risk of bias across all studies and for each item in the individual studies. See <a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a> for individual information about 'Risk of bias' assessments across the trials. </p> <p>The early‐published studies had significant threats to validity and were at risk of selection bias due to their lack of clarity or biased study methodology including sequence generation and allocation concealment (<a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>; <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). These studies were also hampered by inadequate power due to small sample size. Study protocols were not available for these studies, and therefore it is unclear whether they were free of reporting bias. </p> <p>All studies were at risk of performance and detection bias due to the nature of the intervention (platelet transfusion) and the difficulty in blinding participants and outcome assessors to the intervention group of participants. There may be a high level of subjectivity when reporting outcomes such as bleeding, particularly the assessment and classifying of bleeding events. </p> <p>Those studies that published interim data results were at risk of bias. The findings of the interim analysis may have affected the behaviour of the physicians at participating sites and other centres with regard to recruitment of participants, assessment and reporting of bleeding outcomes, and prescription of platelet transfusions. </p> <p>Most studies were at unclear risk of attrition bias, due to insufficient information provided regarding completeness of data and management of missing data. </p> <p>Only one study was deemed to be at low risk of bias (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>), apart from the risk of bias due to lack of blinding. </p> <p>Overall, the quality of evidence per outcome was low to moderate according to the GRADE approach. </p> <p>The outcomes time to first bleeding episode and number of participants with at least one bleeding episode within 30 days from the start of the study were not estimable due to the differences in the way bleeding was assessed in the two studies. </p> <p>The outcome mortality from all causes up to 30 days was not estimable, as only one of the studies reported any deaths in either study arm (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). </p> <p>The outcome quality of life was not estimable, as none of the six studies reported any quality‐of‐life outcomes. </p> <p>We downgraded the estimable outcomes 'number of days with significant bleeding per participant', 'number of participants with severe or life‐threatening bleeding', and 'number of platelet transfusions per participant up to 30 days from the start of the study' by one point for risk of performance and detection bias, due to the lack of blinding. </p> <p>We downgraded the outcome 'number of participants with severe or life‐threatening bleeding up to 30 days from the start of the study' by one point for imprecision due to the wide confidence intervals of the pooled estimates and individual trials contributing to this outcome. </p> </section> <section id="CD010981-sec-0120"> <h3 class="title" id="CD010981-sec-0120">Potential biases in the review process</h3> <p>To our knowledge, our review process is free from bias. We conducted a comprehensive search of data sources (including multiple databases and clinical trial registries) to ensure that we would capture all relevant trials. We made no restrictions for the language in which the paper was originally published. We carefully assessed the relevance of each paper identified and performed all screening and data extractions in duplicate. </p> <p>We prespecified all outcomes and subgroups prior to analysis. One of the limitations of this is that we were unable to include the bleeding data and mortality rates from a number of studies because their outcomes were reported over different time frames. </p> <p>The number of included trials was insufficient for us to complete a funnel plot to examine the risk of publication bias. </p> <p>One potential bias in our review was that we prespecified in the protocol that we would not perform meta‐analysis if there was considerable statistical heterogeneity (I<sup>2</sup> above 80%). This resulted in us being unable to perform a meta‐analysis for our primary outcome. We identified a valid reason for this statistical heterogeneity, and therefore not performing a meta‐analysis was in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD010981-bbs2-0163" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). </p> <p>One of the authors of this review was a primary investigator of a study included in the systematic review. This author's involvement in the review process was in protocol development and as a content expert; the author was not directly involved in data collection, analysis, or the 'Risk of bias' assessment. </p> </section> <section id="CD010981-sec-0121"> <h3 class="title" id="CD010981-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>Two platelet transfusion reviews were recently published in this area (<a href="./references#CD010981-bbs2-0185" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2014 [Epub ahead of print]. [DOI: 10.1111/trf.12943]">Kumar 2014</a>; <a href="./references#CD010981-bbs2-0146" title="ZellerMP , Al-HabsiaKS , HeddleNM . Prophylactic platelet transfusions: should they be a treatment of the past?Current Opinion in Hematology2014;21(6):521-7. ">Zeller 2014</a>). </p> <p><a href="./references#CD010981-bbs2-0146" title="ZellerMP , Al-HabsiaKS , HeddleNM . Prophylactic platelet transfusions: should they be a treatment of the past?Current Opinion in Hematology2014;21(6):521-7. ">Zeller 2014</a> reviewed only the two most recent trials by <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> and provides a descriptive analysis of these studies. The study authors' main conclusions were that patients receiving induction chemotherapy for acute leukaemia should continue to receive prophylactic platelet transfusions during their treatment, and patients undergoing autologous HSCT who are at low risk of bleeding in expert centres with careful monitoring may be candidates for therapeutic‐only platelet transfusion. </p> <p><a href="./references#CD010981-bbs2-0185" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2014 [Epub ahead of print]. [DOI: 10.1111/trf.12943]">Kumar 2014</a> performed a systematic review of the use of platelet transfusions in common clinical settings, including the comparison of prophylactic versus therapeutic platelet transfusions. Their review identified only five studies (<a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>; <a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>; <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). The review authors performed meta‐analyses when the included studies had very different durations of observation (for example for bleeding outcomes this was from 30 days in <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> to 20.4 months in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a>. Their review did not perform a detailed assessment of the risk of bias of the included studies, nor did it consider reasons for heterogeneity between the included studies. The associated guideline recommended that platelets should be transfused prophylactically in order to reduce the risk of spontaneous bleeding in hospitalised adult patients with therapy‐induced hypoproliferative thrombocytopenia (<a href="./references#CD010981-bbs2-0181" title="KaufmanRM , DjulbegovicB , GernsheimerT , KleinmanS , TinmouthAT , CapocelliKE , et al. Platelet transfusion: a clinical practice guideline from AABB. Annals of Internal Medicine 2014 [Epub ahead of print]. [DOI: 10.7326/M14-1589]">Kaufman 2014</a>). </p> <p>Our review is more comprehensive and identifies a study not previously reviewed, <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a>, as well as previously unpublished study data. We performed a detailed quality assessment of all identified studies and highlighted their weaknesses and shortcomings. We noted the high degree of heterogeneity between studies, the different units of analysis, and different time periods over which outcomes have been reported in the different studies, and concluded that it is not possible to combine the individual studies' results in a meta‐analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010981-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram for original review (1950 to January 2002), updated search (January 2002 to November 2011), and current review (November 2011 to 23 July 2015)" data-id="CD010981-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram for original review (1950 to January 2002), updated search (January 2002 to November 2011), and current review (November 2011 to 23 July 2015) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010981-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010981-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 1: Number of participants with at least one bleeding episode" data-id="CD010981-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 1: Number of participants with at least one bleeding episode </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 2: Number of days with significant bleeding per patient" data-id="CD010981-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 2: Number of days with significant bleeding per patient </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 3: Number of participants with severe or life threatening bleeding" data-id="CD010981-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 3: Number of participants with severe or life threatening bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 4: Time to first bleeding event (Hazard Ratio)" data-id="CD010981-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 4: Time to first bleeding event (Hazard Ratio) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 5: Mortality from all causes within 30 days from the start of the study" data-id="CD010981-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 5: Mortality from all causes within 30 days from the start of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 6: Mortality due to bleeding within 90 days from the start of the study" data-id="CD010981-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 6: Mortality due to bleeding within 90 days from the start of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 7: Mean number of platelet transfusions per patient" data-id="CD010981-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 7: Mean number of platelet transfusions per patient </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 8: Mean number of red cell transfusions per patient" data-id="CD010981-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 8: Mean number of red cell transfusions per patient </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 9: Proportion of patients requiring surgical or other intervention" data-id="CD010981-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 9: Proportion of patients requiring surgical or other intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 10: Proportion of patients requiring additional medical interventions required to stop bleeding" data-id="CD010981-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 10: Proportion of patients requiring additional medical interventions required to stop bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 11: Proportion of patients requiring additional products to stop bleeding" data-id="CD010981-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 11: Proportion of patients requiring additional products to stop bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 12: Patients achieving complete remission" data-id="CD010981-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 12: Patients achieving complete remission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 13: Adverse effects of transfusion" data-id="CD010981-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 13: Adverse effects of transfusion </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 14: Number of participants with at least one bleeding episode per disease category." data-id="CD010981-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 14: Number of participants with at least one bleeding episode per disease category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 15: Number of participants with at least one bleeding episode per treatment category." data-id="CD010981-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 15: Number of participants with at least one bleeding episode per treatment category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 16: Number of days with significant bleeding per patient per treatment category" data-id="CD010981-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 16: Number of days with significant bleeding per patient per treatment category </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 17: Number of participants with severe or life threatening bleeding receiving autologous haematopoietic stem cell transplantation" data-id="CD010981-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 17: Number of participants with severe or life threatening bleeding receiving autologous haematopoietic stem cell transplantation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 18: Number of participants with severe or life threatening bleeding receiving chemotherapy/allogeneic haematopietic stem cell transplantation" data-id="CD010981-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 18: Number of participants with severe or life threatening bleeding receiving chemotherapy/allogeneic haematopietic stem cell transplantation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 19: Time to first bleeding event per treatment category" data-id="CD010981-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 19: Time to first bleeding event per treatment category </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010981-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/urn:x-wiley:14651858:media:CD010981:CD010981-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 20: Number of participants with at least one bleeding episode per age category" data-id="CD010981-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_t/tCD010981-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion, Outcome 20: Number of participants with at least one bleeding episode per age category </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/media/CDSR/CD010981/image_n/nCD010981-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010981-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation<br/><b>Settings:</b> Hospital inpatient or outpatient setting<br/><b>Intervention:</b> a therapeutic‐only platelet transfusion policy<br/><b>Comparison:</b> a prophylactic platelet transfusion policy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion policy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion policy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 1 bleeding episode up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An estimate of the level of effect could not be made due to differences in the way bleeding was assessed in the 2 studies. A higher proportion of participants had WHO Grade 2 or above bleeding in the therapeutic‐only policy arms in both studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days with significant bleeding per participant up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days with significant bleeding per participant in the intervention groups was<br/><b>0.5 higher</b><br/>(0.1 to 0.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>599</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study reported this outcome over a 30 day follow‐up period (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants with severe or life‐threatening bleeding up to 30 days from study entry</b><br/>Modified WHO grading scale </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.91</b> <br/>(0.86 to 28.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(3 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(2 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first bleeding episode up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An estimate of the level of effect could not be made due to differences in the way bleeding was assessed in the 2 studies. The time to first WHO Grade 2 or above bleeding episode was shorter in the therapeutic‐only policy arms in both studies. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from all causes up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>629<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 of these 2 studies reported any deaths in either study arm (<a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>). There were 5 deaths in the therapeutic arm (301 participants) and 4 deaths in the prophylactic arm (299 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of platelet transfusions per participant in the intervention groups was<br/><b>0.50 lower</b><br/>(0.63 to 0.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the 6 studies reported any quality‐of‐life outcomes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the quality of evidence by 1 for risk of performance bias and detection bias, due to the lack of blinding.<br/><sup>2</sup> We downgraded the quality of evidence by 1 for imprecision due to wide confidence intervals of the pooled estimates and individual trials contributing to this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Therapeutic versus prophylactic platelet transfusion studies ‐ characteristics of studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Characteristics of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Type of platelet product</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcome</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with a haematological malignancy receiving myelosuppressive chemotherapy or undergoing autologous HSCT </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusions were not given if the plt count was &lt; 10 x 10<sup>9</sup>/L vs </p> <p>plt transfusions were given at a threshold plt count of &lt; 10 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median days on study was 30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled plt products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occurence of a WHO Grade 2 bleed or above</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with AML or undergoing autologous HSCT for leukaemia in remission, non‐Hodkgin lymphoma, Hodkgin's disease, or myeloma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusions were only given for WHO Grade 2 bleeds or higher vs plt transfusions were given at a threshold plt count of &lt; 10 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When plt count was self sustaining at more than 20 x 10<sup>9</sup>/L for 2 days, or a maximum of 30 days, or at hospital discharge, or treatment failure, death or at study withdrawal, whichever occurred first </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled plt products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of plt transfusions during standardised observation period of 14 days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with amegakaryocytic</p> <p>thrombocytopenia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given for clinically significant bleeding and just prior to invasive procedures vs prophylactic plt transfusion given if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equally given single‐donor and random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion give in presence of 5 clinical indicators of bleeding vs prophylactic plt transfusion given if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding outcomes and plt transfusion requirements were reported at 10 months.</p> <p>Mean follow‐up of 19.9 months to 20.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given in presence of haemorrhage vs prophylactic platelet transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with AML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plt transfusion given if clinically significant bleeding or &gt; 50% fall in plts to &lt; 20 x 10<sup>9</sup>/L in previous 24 hours vs prophylactic plt transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random‐donor plts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AML: acute myeloid leukaemia<br/>HSCT: haematopoietic stem cell transplantation<br/>plt: platelet </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Therapeutic versus prophylactic platelet transfusion studies ‐ characteristics of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Method of bleeding assessment and grading</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bleeding primary outcome of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method of bleeding assessment reported</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Clinically significant bleeding definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bleeding severity scale used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RBC usage part of bleeding severity assessment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RBC transfusion policy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO Grade 2 or higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified WHO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the absence of bleeding a Hb &lt; 90 g/L</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO Grade 2 or higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified WHO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To maintain a Hb &gt; 80 g/L</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and severe bleeds.</p> <p>Mild bleeds not requiring active intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study specific</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study specific</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Hb: haemoglobin<br/>RBC: red blood cell </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Method of bleeding assessment and grading</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Clinically significant bleeding event/participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Statistical analysis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Percentage</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjusted difference in proportions</p> <p>8.4%</p> <p>(90% CI 1.7, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a><b><sup> a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> <p>(301 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42%</p> <p>(36, 48) reported per treatment cycle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> <p>(343 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19%</p> <p>(14, 23)</p> <p>reported per treatment cycle</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% vs 19%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.0001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup> b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> <p>(0.86, 1.18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup> c</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.58</p> <p>(1.67, 12.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup>d</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.83</p> <p>(0.94, 3.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CI: confidence interval<br/>RR: risk ratio </p> <p><sup>a</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, bleeding was reported per treatment cycle. Participants were followed until either the platelet count was self sustaining at 20 x 10<sup>9</sup>/L or higher for 2 days, a maximum of 30 days, at hospital discharge, when treatment failure occurred, at death or at study withdrawal, whichever occurred first. Only participants receiving autologous haematopoietic stem cell transplantation received one treatment cycle, and therefore the number of participants was equal to the number of treatment cycles. Participants receiving chemotherapy could have received up to seven cycles of treatment. </p> <p><sup>b</sup> Bleeding events in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count less than 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>c</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were not reported over this review's predefined outcome period of 30 days. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported bleeding outcome over the first 10 months of the study. </p> <p><sup>d</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were also reported from study enrolment until study closure. The mean number of months observed varied from 19.9 months in the prophylactic group to 20.4 months in the therapeutic group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Clinically significant bleeding event/participant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Total number of days on which significant bleeding event occurred per participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Therapeutic‐only platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Prophylactic platelet transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Days of clinically significant bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Days of clinically significant bleeding</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.7 +/‐ 2.9 (SD)</p> <p>days per participant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.2 +/‐ 2.0 (SD)</p> <p>days per participant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 1.52</p> <p>(1.14, 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.004</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a><b><sup>b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>SD: standard deviation</p> <p><sup>a</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were not reported over this review's predefined outcome period of 30 days. <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> reported bleeding outcome over the first 10 months of the study. </p> <p><sup>b</sup> Bleeding events in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were also reported from study enrolment until study closure. The mean number of months observed varied from 19.9 months in the prophylactic group to 20.4 months in the therapeutic group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Total number of days on which significant bleeding event occurred per participant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Number of participants with at least one episode of severe or life‐threatening bleeding</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants with severe bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 4</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3 + 4</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>WHO Grade 3 and 4</p> <p>Odds ratio</p> <p>6.05</p> <p>(0.73, 279.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> <th align="left" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of</b> participants<b>with severe bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants with severe bleeding per treatment cycle</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 3</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>WHO Grade 4</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Statistics used</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a><b><sup> b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 (301 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.0159</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (343 treatment cycles)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup> Bleeding events in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>b</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, bleeding was reported per treatment cycle. Participants were followed until either the platelet count was self sustaining at 20 x 10<sup>9</sup>/L or higher for 2 days, a maximum of 30 days, at hospital discharge, when treatment failure occurred, at death or at study withdrawal, whichever occurred first. Only participants receiving autologous haematopoietic stem cell transplantation received one treatment cycle, and therefore the number of participants was equal to the number of treatment cycles. Participants receiving chemotherapy could have received up to seven cycles of treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Number of participants with at least one episode of severe or life‐threatening bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Mortality</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality as per study definition</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study follow‐up definitions</b> </p> </th> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality within 30 days</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mortality within 90 days</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to bleeding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Due to infection</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All cause/ due to bleeding/ due to infection</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study follow‐up was when plt count was self sustaining at more than 20 x 10<sup>9</sup>/L for 2 days, or a maximum of 30 days, or at hospital discharge, or treatment failure, death or at study withdrawal, whichever occurred first. </p> <p>Participants receiving chemotherapy could have received up to 7 cycles of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Mortality reported within 1 month/course of chemotherapy</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality reported within 1 month/course of chemotherapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L). This often included more than 1 period of thrombocytopenia per participant. </p> <p>Bacterial or fungal sepsis (or both) was a contributing factor in 8 of the deaths.</p> <p>11 of the 14 haemorrhagic deaths were in participants who had plt alloantibodies</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 20.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 19.9 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study follow‐up not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>plt: platelet</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Number of platelet transfusions or units</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet dose/transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet transfusions/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet units transfused/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 adult unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 +/‐ 2.6 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio 0.62</p> <p>(0.51, 0.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 +/‐ 3.3 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.67</p> <p>(0.55, 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 +/‐ 3.2 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 +/‐ 3.6 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.30</p> <p>(‐1.85, ‐0.75)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 platelet unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.63</p> <p>(1.4, 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33.5% reduction in platelet transfusion</p> <p>(22.2, 43.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.0001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.44</p> <p>(2.2, 2.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>b</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐donor unit comprised a mean of 6.8 platelet concentrates, with an average yield of 0.8 x 10<sup>11</sup> plts/unit. </p> <p>Single‐donor unit had a mean of 4.8 x 10<sup>11</sup> plts/collection </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a><b><sup>c</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 units/m<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8/participant<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1/participant<sup>d</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Number in each arm not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 x 10<sup>11</sup> plts/transfusion </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet dose/transfusion</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet transfusions/course of chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of platelet units transfused/course of chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.1 +/‐ 3.4 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐15.8 (‐19.2, ‐12.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.9 +/‐ 5.9 (SD)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>MD: mean difference<br/>SD: standard deviation </p> <p><sup>a</sup> In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, the analysis was adjusted for the stratification variables age (&lt; 50 years and ≥ 50 years) and sex, and a random effect for repeated measures data of a participant’s treatment cycles clustered in centres. </p> <p><sup>b</sup> Platelet transfusions in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> <p><sup>c</sup> Platelet transfusions in <a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. ">Murphy 1982</a> were reported over a 10‐month period. </p> <p><sup>d</sup> Not specified whether this value is a mean or a median (no further information available ‐ author has died) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Number of platelet transfusions or units</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Number of red cell transfusions per participant</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell transfusions/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell units/participant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="9" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). "><b>Stanworth 2013</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.5 +/‐ 1.8 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rate ratio</p> <p>1.14</p> <p>(0.96, 1.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 3.0 +/‐ 3.4 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate Ratio</p> <p>1.24</p> <p>(1.04, 1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 1.5 +/‐ 1.7 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 2.8 +/‐ 3.1 (SD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.20</p> <p>(‐0.32, 0.72)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. "><b>Wandt 2012</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 3.14</p> <p>(2.81, 3.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 2.85</p> <p>(2.58, 3.12)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a><b><sup>a</sup> </b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>Number in each arm not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants in each arm</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell transfusions/course of treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of red cell units/course of treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>statistics</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0004" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet1978;1 (8058):267. "><b>Solomon 1978</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 +/‐ 1.0 (SE)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐0.6</p> <p>(‐1.34, 0.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 +/‐ 1.0 (SE)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>MD: mean difference<br/>SD: standard deviation<br/>SE: standard error </p> <p><sup>a</sup> Red cell transfusions in <a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. ">Grossman 1980</a> were not reported over this review's predefined outcome period of 30 days. Participants were followed throughout their initial hospital stay and all subsequent admissions. Days on study was defined as a platelet count &lt; 50 x 10<sup>9</sup>/L, and the mean length of follow‐up was 41.6 days in the therapeutic‐only group and 42.7 days in the prophylactic group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Number of red cell transfusions per participant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Platelet refractoriness</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Platelet refractoriness</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Definition of platelet refractoriness</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of study</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Intermediate‐length follow‐up (30 to 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0001" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic vs. therapeutic platelet transfusions. In: International Society Blood Transfusion Abstract Book. 1980:271. "><b>Grossman 1980</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Corrected count increment of &lt; 10 x 10<sup>9</sup>/L following 2 or more consecutive transfusions in the absence of fever, disseminated intravascular coagulopathy, splenomegaly, or sepsis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean days on study was 42 days (defined as plt count &lt; 50 x 10<sup>9</sup>/L). This often included more than 1 period of thrombocytopenia per participant </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Long‐term follow‐up (&gt; 90 days)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0002" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347-56. "><b>Murphy 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding for more than 4 days in which thrombocytopenia persists in the face of repeated platelet transfusions </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 20.4 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean follow‐up 19.9 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Follow‐up period not reported</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><a href="./references#CD010981-bbs2-0003" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single-donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. "><b>Sintnicolaas 1982</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Platelet refractoriness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010981-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Subgroup analyses for disease and treatment category</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="2" rowspan="1" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Acute leukaemia</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymphoma or myeloma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CML or other cancer</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Autologous stem cell transplant</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Chemotherapy</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Allogeneic stem cell transplant</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants with at least 1 clinically significant bleeding episode<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.64</p> <p>(1.11, 2.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07</p> <p>(0.88, 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07</p> <p>(0.50, 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.55</p> <p>(1.05, 2.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50</p> <p>(0.86, 2.61)</p> </td> </tr> <tr> <td align="left" class="headercell" colspan="2" rowspan="1" valign="bottom"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Acute leukaemia</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Lymphoma or myeloma</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CML or other cancer</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Autologous stem cell transplant</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Chemotherapy/</b> </p> <p><b>Allogeneic stem cell transplant</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Total number of days on which bleeding occurred per participant<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>599</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 1.52</p> <p>(1.14, 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.30</p> <p>(‐0.07, 0.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MD 1.20</p> <p>(0.22, 2.18)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants with at least 1 episode of severe or life‐threatening bleeding<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.91 <br/>(0.86, 28.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.89</p> <p>(0.58, 41.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>RR 2.97</p> <p>(0.31, 27.98)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Time to first bleeding episode<sup>1</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>179</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.70</p> <p>(‐3.16, 1.76)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MD ‐6.00</p> <p>(‐9.52, ‐2.48)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CI: confidence interval<br/>CML: chronic myelogenous leukemia<br/>MD: mean difference<br/>RR: risk ratio </p> <p><sup>1</sup> Follow‐up: median 30 days. Length of follow‐up in the primary study contributing to this outcome was 30 days. Bleeding assessed using modified WHO grading scale. </p> <p><sup>2</sup> A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, a therapeutic‐only transfusion policy was associated with increased risk of bleeding events per treatment cycle when compared with a prophylaxis policy (RR 3.45, 95% CI 1.66 to 7.17). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the 95% CI crossed 1.0 (RR 1.17, 95% CI 0.99 to 1.39). </p> <p><sup>3</sup>A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, there was no statistically significant difference in the number of clinically significant bleeding episodes between a therapeutic‐only or prophylactic platelet transfusion policy (RR 1.04, 95% CI 0.85 to 1.28). However, in <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> there was a statistically significant difference (RR 3.45, 95% CI 1.66 to 7.17). </p> <p><sup>4</sup>A meta‐analysis of the data from <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a> and <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a> was not performed due to the significant statistical heterogeneity seen. The observed statistical heterogeneity may relate to the different methods used in studies in the assessment and grading of bleeding (<a href="./references#CD010981-sec-0154" title="">Characteristics of included studies</a>). In <a href="./references#CD010981-bbs2-0005" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al, TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394–403. ISRCTN08758735. A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled-trials.com/ISRCTN08758735. Accessed 6 February 2010. PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions -- how was consistency achieved. [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. In: Transfusion Medicine. 2013:46-7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163-71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no-prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non-inferiority trial. Blood2012;120:Supplement 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385-93. StanworthSJ , EstcourtLJ , PowetG , KahanBC , DyerC , ChooL , et al, for the TOPPS Investigators*. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771-80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740-7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):(Abstract). ">Stanworth 2013</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (hazard ratio 1.30, 95% CI 1.03 to 1.64). In <a href="./references#CD010981-bbs2-0006" title="NCT00521664. A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664. Accessed 4 January 2010. Schaefer-EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):(Abstract). Schaefer-EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):(Abstract). WandtH , Schäfer-EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high-dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):(Abstract). WandtH , Schaefer-EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):(Abstract). WandtH , Schaefer-EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet2012;380(9850):1309-16. WandtH , WendelinK , Schaefer-EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>, the time to onset of significant bleeding was shorter in the therapeutic‐only group than in the prophylaxis group (hazard ratio 2.61, 95% CI 1.84 to 3.72). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Subgroup analyses for disease and treatment category</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/full#CD010981-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010981-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of participants with at least one bleeding episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of days with significant bleeding per patient <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of participants with severe or life threatening bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.86, 28.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to first bleeding event (Hazard Ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mortality from all causes within 30 days from the start of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mortality due to bleeding within 90 days from the start of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Mean number of platelet transfusions per patient <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.63, ‐0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mean number of red cell transfusions per patient <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.14, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Proportion of patients requiring surgical or other intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.96 [0.44, 35.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Proportion of patients requiring additional medical interventions required to stop bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Proportion of patients requiring additional products to stop bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.14, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Patients achieving complete remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse effects of transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.62, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Number of participants with at least one bleeding episode per disease category. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Patients with Acute leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Patients with lymphoma or myeloma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Patients with CML or other cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Number of participants with at least one bleeding episode per treatment category. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Patients undergoing autologous haematopoietic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Patients receiving chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Patients receiving allogeneic haematopoietic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Number of days with significant bleeding per patient per treatment category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Participants undergoing autologous haematopoietic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Participants receiving chemotherapy/allogeneic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Number of participants with severe or life threatening bleeding receiving autologous haematopoietic stem cell transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Number of participants with severe or life threatening bleeding receiving chemotherapy/allogeneic haematopietic stem cell transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Time to first bleeding event per treatment category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Participants undergoing autologous haematopoietic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Participants receiving chemotherapy/allogeneic stem cell transplantation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Number of participants with at least one bleeding episode per age category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Age greater than or equal to 60 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Age 18 to less than 60 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Therapeutic or non‐prophylactic platelet transfusion versus prophylactic platelet transfusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010981.pub2/references#CD010981-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010981.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010981-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010981-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010981-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010981-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010981-note-0016">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010981-note-0014">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010981\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010981\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010981\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010981\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010981\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010981.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010981.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010981.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010981.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010981.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716476259"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010981.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716476262"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010981.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da06e8f0e9379',t:'MTc0MDcxNjQ3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 